CRB1 Retinal Dystrophies

Mendelian MONDO:0013453 Pathograph 15 Show in embeddings browser Ophthalmological Disease Retinal Dystrophy Inherited retinal dystrophy

CRB1-associated retinal dystrophies are a spectrum of autosomal recessive inherited retinal diseases caused by biallelic pathogenic variants in CRB1, encoding Crumbs homolog 1. CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis. Loss of CRB1 disrupts adherens junctions at the outer limiting membrane, leading to progressive photoreceptor degeneration. The clinical spectrum ranges from severe early-onset Leber congenital amaurosis (LCA8), through retinitis pigmentosa (RP12) with onset in the first two decades, to milder macular dystrophy. Distinctive features across the family include abnormally thickened and disorganized retinal lamination, nummular pigment deposits, preserved para-arteriolar retinal pigment epithelium (PPRPE), and Coats-like exudative vasculopathy. The differential phenotype is influenced by modifying factors in addition to the specific CRB1 allele combination, with null variants enriched in the EOSRD/LCA subtype. CRB1 is expressed in the retina as two isoforms in different cells - CRB1-A in Muller glia and CRB1-B in photoreceptors - and which of them a variant disrupts is a further determinant of where on the spectrum a patient falls.

Ask OpenScientist

Ask a research question about CRB1 Retinal Dystrophies. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
11
Phenotypes
2
Hypotheses
4
Gaps
15
Pathograph
1
Genes
3
Subtypes
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
CRB1-associated retinal dystrophies follow autosomal recessive inheritance. Biallelic pathogenic variants (two mutant alleles in trans) are required for disease manifestation. Over 150 CRB1 sequence variants have been reported in more than 240 patients.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"Mutations in the CRB1 gene are associated with variable phenotypes of severe retinal dystrophies, ranging from leber congenital amaurosis (LCA) to rod-cone dystrophy, also called retinitis pigmentosa (RP)."
This meta-analysis of CRB1 mutations confirms the autosomal recessive inheritance pattern across the retinal dystrophy spectrum.
◆

Subtypes

3
Leber Congenital Amaurosis 8 (EOSRD/LCA) MONDO:0013453
~52%
Severe early-onset branch with congenital or infantile visual impairment, nystagmus, and non-recordable electroretinogram. The EOSRD/LCA phenotype is significantly associated with null CRB1 variants. Severe visual impairment occurs after age 20 in most patients.
Show evidence (2 references)
PMID:36099972 SUPPORT Human Clinical
"26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
This multicenter cohort shows EOSRD/LCA as the most frequent CRB1 subtype at 52%.
PMID:36099972 SUPPORT Human Clinical
"EOSRD/LCA phenotype was significantly associated with null variants"
Confirms the association of null CRB1 variants with the severe EOSRD/LCA phenotype.
Retinitis Pigmentosa 12 MONDO:0010818
~25%
Rod-predominant retinal dystrophy branch with symptom onset in the first two decades (median age 4 years). Progressive peripheral field loss and night blindness, with severe visual impairment most frequent after age 40. A subset presents with mild, adult-onset disease.
Show evidence (2 references)
PMID:36099972 SUPPORT Human Clinical
"26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
This cohort identifies RP as 25% of CRB1-associated retinal dystrophies.
PMID:28341475 SUPPORT Human Clinical
"For the RP patients, the median age at symptom onset was 4.0 years."
Long-term follow-up study documents onset age and progressive course in CRB1-RP patients.
CRB1-Associated Macular Dystrophy MONDO:0020242
~23%
Macular-predominant branch with central visual decline and relatively preserved peripheral vision. The 167_169 deletion was exclusively present in this cohort.
Show evidence (2 references)
PMID:36099972 SUPPORT Human Clinical
"26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
This multicenter cohort identifies macular dystrophy as 23% of CRB1-associated retinal dystrophies.
PMID:36099972 SUPPORT Human Clinical
"167_169 deletion was exclusively present in the MD cohort"
Confirms a specific genotype-phenotype correlation for the macular dystrophy branch.
◈

Mechanistic Hypotheses

2
Muller-glial CRB1-A loss is the necessary lesion in human disease
crb1a_muller_glial_primacy CANONICAL
Evidence balance 2 support
Human disease requires the Muller-glial isoform to be hit. No patient has yet been reported whose variants affect CRB1-B alone, and a cohort reappraisal that scored predicted isoform dosage per patient concluded that severity tracks with the CRB1-A lesion. On this model the outer limiting membrane fails from the glial side, and the photoreceptor isoform modifies the picture rather than initiating it.
Pathograph links
Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors -> Loss of CRB1 at the outer limiting membrane DIRECT Whichever isoform is disrupted, the lesion is delivered to the same structure: CRB1-A and CRB1-B are both present at the outer limiting membrane, on the Muller-cell and photoreceptor sides of the adherens junctions respectively.
Show evidence (2 references)
PMID:41626423 SUPPORT Human Clinical
"Crumbs homolog 1-A must be affected for disease manifestation, while sparing of CRB1-B leads to milder phenotypes."
States the necessity claim directly, from the largest CRB1 genotype series to date.
PMID:34884448 SUPPORT Human Clinical
"In humans, the retinal degeneration appears early, and the phenotype is mainly driven by the Müller cell isoform A impairment."
Independent cohort assigning the severity-determining role to the Muller-cell isoform in humans.
Preserved photoreceptor CRB1-B attenuates disease to macular-limited dystrophy
crb1b_sparing_attenuates EMERGING
Evidence balance 2 support 1 refute
A second, contested claim: beyond requiring CRB1-A to be hit, the phenotype is graded by whether CRB1-B survives. Two recent cohorts find preserved wild-type CRB1-B enriched in macular-limited disease and CRB1-A-only variants associated with macular dystrophy. An earlier cohort that scored the same variable reached the opposite conclusion, so this is curated as emerging rather than settled - see the crb1_isoform_b_severity_conflict discussion.
Pathograph links
Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors -> Macular dystrophy INDIRECT UNKNOWN INTERMEDIATES Proposed route to the macular-limited end of the spectrum: when the variant combination leaves photoreceptor CRB1-B intact, the retained adult-retina isoform is held to limit the lesion to the macula. The intermediate steps between preserved CRB1-B and macular-restricted degeneration are not known, and this edge belongs to an emerging hypothesis that one cohort contradicts.
Show evidence (3 references)
PMID:41358656 SUPPORT Human Clinical
"The proportion of patients harboring biallelic variants expressing wild-type CRB1-B was significantly higher in the maculopathy group (30.8%) than in the pan-retinopathy group (8.1%)."
Direct cohort support for CRB1-B preservation grading the phenotype toward macular-limited disease.
PMID:41626423 SUPPORT Human Clinical
"Mutations specific to CRB1-A, sparing CRB1-B were associated with MD."
Replicates the association between CRB1-B sparing and macular dystrophy at n=389 across 50 cohorts.
PMID:34884448 REFUTE Human Clinical
"The CRB1 isoform B has no impact on the severity of the phenotype as EORD, RP and macular dystrophy can occur regardless of the level of isoform B"
A 50-patient cohort that scored predicted isoform-B dosage per patient found no severity effect, directly contradicting this hypothesis.
?

Discussions and Knowledge Gaps

4
Does preserved photoreceptor CRB1-B actually attenuate CRB1 retinopathy, or is the association with macular-limited disease carried entirely by which CRB1-A variants happen to spare it?
CONTROVERSY OPEN crb1_isoform_b_severity_conflict
Attached to
mechanistic_hypotheses#crb1b_sparing_attenuates pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
Three cohorts have scored the same variable and disagree. Two recent series (n=75 and n=389) find wild-type CRB1-B enriched in macular-limited disease and CRB1-A-only variants associated with macular dystrophy. An earlier series (n=50) scored predicted isoform dosage patient by patient and found the opposite: it reports patients with fully preserved isoform B who nonetheless had early-onset retinal dystrophy, and patients with the macular c.498_506del variant who developed macular dystrophy irrespective of isoform-B status. The disagreement is not merely one of cohort size, because the alternative reading is confounding rather than noise: the exon-2 variants that spare CRB1-B are also the mildest CRB1-A lesions, so isoform-B preservation may be a marker of a mild CRB1-A allele rather than a protective factor in its own right. All three cohorts report predicted, not measured, isoform dosage.
Proposed experiments
Measured isoform dosage in patient iPSC-derived retinal organoids stratified by phenotype
crb1_isoform_dosage_organoid_series
Derive retinal organoids from patients matched for predicted CRB1-A lesion severity but differing in whether CRB1-B is spared, and quantify CRB1-A and CRB1-B transcript and protein directly instead of predicting them from exon position. Score outer limiting membrane integrity and photoreceptor lamination.
Would support
pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
Supporting outcome
  • Among patients matched on CRB1-A lesion severity, those retaining measured CRB1-B protein show better preserved outer limiting membrane and lamination than those who do not.
Refuting outcome
  • Organoid phenotype tracks with measured CRB1-A dosage alone, with no residual effect of CRB1-B once CRB1-A severity is matched.
Show evidence (3 references)
PMID:34884448 SUPPORT Human Clinical
"Furthermore, all patients with the specific c.498_506del macular variant developed a macular dystrophy regardless of the impact on isoform B."
The observation on which the dissenting cohort rests: within carriers of the macular variant, isoform-B status made no difference.
PMID:41358656 SUPPORT Human Clinical
"Patients with biallelic loss-of-function variants were significantly more prevalent in the pan-retinopathy group (40.3%) than in the maculopathy group (7.1%) (P = 0.03)."
Shows that allele severity itself also separates the two groups, which is the confound the isoform claim has to be disentangled from.
PMID:41626423 SUPPORT Human Clinical
"Macular dystrophy was not exclusively seen because of preservation of CRB1-B on one allele, as it also appeared in patients with variants affecting CRB1-B in both alleles."
States the confound in the source's own words: the macular phenotype arises even when CRB1-B is disrupted on both alleles, so CRB1-B preservation is not necessary for it. The same paper attributes those cases to CRB1-A missense variants predicted to have minimal structural impact, which is the mild-allele reading rather than a protective isoform effect.
Mouse work makes Crb1-B the essential isoform while human cohorts make CRB1-A the essential one - is that a real species difference, or an artefact of what human sequencing panels can see?
HUMAN MODEL MISMATCH OPEN crb1_isoform_hierarchy_mouse_versus_human
Attached to
pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors mechanistic_hypotheses#crb1a_muller_glial_primacy
Isoform-selective mouse alleles put Crb1-B in the primary role: retinal anomalies develop in the mouse even when Crb1-A is normal. Human cohorts invert this, reporting that CRB1-A is universally affected and appears to drive severity. The mismatch cannot currently be resolved on the human side, because diagnostic sequencing panels do not cover the promoter and terminal exons unique to the CRB1-B transcript, so a human counterpart of the isoform-B-selective mouse genotype would not be detected even if it existed. The human evidence for CRB1-A primacy is therefore ascertainment-limited, and the apparent species difference should not be treated as established until panels are redesigned. This directly conditions how mouse rescue data should be read when selecting an isoform for gene-supplementation therapy.
Proposed experiments
Resequence CRB1-B-specific promoter and terminal exons in unsolved and monoallelic CRB1 cases
crb1b_specific_region_resequencing
Extend retinal gene panels to the CRB1-B-specific promoter and 5-prime and 3-prime exons, then re-screen patients carrying a single CRB1 variant and patients with unsolved inherited retinal dystrophy.
Would refute
mechanistic_hypotheses#crb1a_muller_glial_primacy
Supporting outcome
  • Patients with biallelic variants confined to CRB1-B-specific regions are identified, showing the human hierarchy was an ascertainment artefact.
Refuting outcome
  • No biallelic CRB1-B-exclusive genotypes are found after adequate coverage, strengthening CRB1-A involvement as a genuine necessary condition.
Show evidence (3 references)
PMID:34884448 SUPPORT Model Organism
"Based on the characterization of the previously known and novel models, Ray et al. stated that, in mice, Crb1-B is essential and predominant, as retinal anomalies can develop even when Crb1-A is strictly normal."
States the mouse hierarchy that the human data invert.
PMID:34884448 SUPPORT Human Clinical
"A human phenotype equivalent to the Crb1delB/null or Crb1delB/delB mouse models has never been reported"
The specific human observation that is missing, and which the panel gap explains.
PMID:41626423 SUPPORT Human Clinical
"All patients had variants affecting CRB1-A, with none exclusively affecting CRB1-B."
The human observation whose interpretation is at stake: universal CRB1-A involvement is consistent both with CRB1-A necessity and with CRB1-B-only genotypes being invisible to the assay.
By what mechanism do CRB1-A-specific variants such as c.498_506del produce macular-restricted rather than generalised retinal disease?
KNOWLEDGE GAP OPEN crb1_macular_dystrophy_mechanism_unmodelled
Attached to
has_subtypes#Macular dystrophy pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
The genotype-phenotype association is now replicated and strong, but no mechanism connects it to a macular topography. The gap is a model gap rather than a data gap: there is no mouse carrying the equivalent in-frame deletion and, at the time of the largest series, no macular-dystrophy CRB1 induced pluripotent stem cell line was available. Structural prediction suggests the deletion destabilises two adjacent EGF-like modules, but that does not explain why the consequence is confined to the macula.
Show evidence (2 references)
PMID:41626423 SUPPORT Human Clinical
"the precise mechanism by which these variants lead to MD remains unclear, largely because of the absence of corresponding mouse models or MD-CRB1 induced pluripotent stem cell lines for further investigation."
States the gap and its cause - the absent model systems - in the authors' own words.
PMID:34884448 SUPPORT Human Clinical
"With the lack of a corresponding mouse model, the mechanism of this variant is not clearly known."
The same gap identified independently four years earlier for the c.498_506del variant specifically.
Should this entry keep the flat LCA8 / RP12 / macular dystrophy split, or move to the pan-retinopathy versus maculopathy axis used by the newer literature?
INTERPRETATION OPEN crb1_subtype_axis_under_review
Attached to
has_subtypes#
The three subtypes here follow the phenotypic diagnoses assigned in a single 104-patient cohort, and all three subtype frequencies come from one sentence in it. Two later series reorganise the same disease along a different axis: a 75-patient cohort treats pan-retinopathy and maculopathy as the two primary phenotypes and calls them distinct entities, which collapses LCA8 and RP12 into severity poles of one branch while setting maculopathy apart on genetic grounds; a 389-patient reclassification under standardised criteria adds cone-rod dystrophy as a fourth phenotype. A counterweight is that in one p.(Pro836Thr) series, imaging that looked macula-confined sat on top of generalised photoreceptor dysfunction on electrophysiology, so a structurally-defined maculopathy category may not be as clean as it appears. Restructuring has_subtypes would also strand the LCA8 and RP12 MONDO groundings, which are the two mappings in this entry that are unambiguously correct. The decision, together with the entry-level disease_term question, is reserved for the maintainer in issue 8997 and is deliberately not taken here; this discussion records the evidence so the choice is not re-derived from scratch.
Show evidence (2 references)
PMID:41358656 SUPPORT Human Clinical
"This study establishes CRB1-associated pan-retinopathy and maculopathy as clinically and genetically distinct entities."
The competing two-way nosology, asserted on combined clinical and genetic grounds.
PMID:40590804 REFUTE Human Clinical
"Although retinal imaging may show alterations confined to the macular region, electrophysiology in this series indicates generalized cone and rod photoreceptor dysfunction."
Cautions against reifying a maculopathy category from imaging, since function was generalised in the same patients.
⚙

Pathophysiology

4
Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
CRB1 is transcribed in the retina as two major isoforms occupying different cells. The canonical 12-exon CRB1-A is expressed in Muller glia and is the predominant isoform during retinal development; the shorter CRB1-B is expressed in photoreceptors and is the more abundant isoform in the adult retina. Both reach the outer limiting membrane from opposite sides of the same junction. Because a variant's exon position determines which transcripts it disrupts, one gene produces cell-type-partitioned lesions rather than a single uniform loss: exon 6, 7 and 9 variants hit both isoforms, whereas exon 2 variants such as c.498_506del p.(Ile167_Gly169del) affect CRB1-A only and leave CRB1-B intact. In the largest genotype series assembled to date every patient carried a variant affecting CRB1-A and none was CRB1-B-exclusive, so CRB1-A involvement appears necessary for disease.
Muller-glial CRB1-A loss is the necessary lesion in human disease Preserved photoreceptor CRB1-B attenuates disease to macular-limited dystrophy
Mueller cell CL:0000636 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Mueller cell (CL:0000636). CL:0000636 is a cell type from the Cell Ontology. photoreceptor cell CL:0000210 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves photoreceptor cell (CL:0000210). CL:0000210 is a cell type from the Cell Ontology.
CRB1 hgnc:2343 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased CRB1 (hgnc:2343). hgnc:2343 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Downstream
Loss of CRB1 at the outer limiting membrane Whichever isoform is disrupted, the lesion is delivered to the same structure: CRB1-A and CRB1-B are both present at the outer limiting membrane, on the Muller-cell and photoreceptor sides of the adherens junctions respectively. Muller-glial CRB1-A loss is the necessary lesion in human disease
Macular dystrophy Proposed route to the macular-limited end of the spectrum: when the variant combination leaves photoreceptor CRB1-B intact, the retained adult-retina isoform is held to limit the lesion to the macula. The intermediate steps between preserved CRB1-B and macular-restricted degeneration are not known, and this edge belongs to an emerging hypothesis that one cohort contradicts. Preserved photoreceptor CRB1-B attenuates disease to macular-limited dystrophy
Show evidence (5 references)
PMID:41626423 SUPPORT Human Clinical
"Crumbs homolog 1-A is primarily expressed in Müller cells and plays a vital role in retinal development, whereas CRB1-B, expressed in photoreceptors, helps maintain long-term retinal integrity in adult retinas."
Establishes the cell-type assignment of the two isoforms and their differing developmental versus maintenance roles.
PMID:34884448 SUPPORT Human Clinical
"CRB1-A is localized to the apical tips of Müller cells and CRB1-B in the inner and outer segments with a gradient"
Gives the subcellular localisation of each isoform, on either side of the outer limiting membrane.
PMID:34884448 SUPPORT Human Clinical
"CRB1-A is the predominant isoform during developmental stages. By contrast, CRB1-B is by far the most abundant isoform in the adult human, as well as murine retina."
Supports the developmental versus adult division of labour between the two isoforms.
+ 2 more references
Loss of CRB1 at the outer limiting membrane
CRB1 localizes to the apical membrane of photoreceptors and Muller glial cells at the outer limiting membrane (OLM), where it maintains adherens junction integrity and cell polarity. Biallelic loss-of-function variants disrupt this structural scaffold, creating the shared proximal defect across the CRB1 disease family.
photoreceptor cell CL:0000210 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves photoreceptor cell (CL:0000210). CL:0000210 is a cell type from the Cell Ontology. Mueller cell CL:0000636 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Mueller cell (CL:0000636). CL:0000636 is a cell type from the Cell Ontology.
CRB1 hgnc:2343 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased CRB1 (hgnc:2343). hgnc:2343 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
adherens junction organization GO:0034332 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased adherens junction organization (GO:0034332). GO:0034332 is a biological process from the Gene Ontology. ↓ DECREASED establishment or maintenance of cell polarity GO:0007163 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased establishment or maintenance of cell polarity (GO:0007163). GO:0007163 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Outer limiting membrane disruption and retinal disorganization Loss of CRB1 disrupts the OLM, leading to fragmented adherens junctions, retinal folds, and pseudorosettes. The resulting thickened and abnormally laminated retina is a hallmark of CRB1 retinopathy.
Keratoconus CRB1-associated disease can include keratoconus, suggesting a corneal structural consequence in addition to retinal degeneration.
Show evidence (2 references)
PMID:12915475 SUPPORT Model Organism
"Shortened photoreceptor inner and outer segments are observed as early as 2 weeks after birth, suggesting a developmental defect in these structures rather than a degenerative process."
The rd8 mouse model demonstrates that CRB1 is essential for photoreceptor morphogenesis and OLM integrity.
PMID:22065545 SUPPORT Human Clinical
"CRB1 consists of 12 exons and exhibits alternative splicing at the 3' end, yielding two proteins of 1376 and 1406 amino acids"
This review describes CRB1 protein structure including transmembrane and cytoplasmic domains critical for junction formation.
Outer limiting membrane disruption and retinal disorganization
Disrupted OLM integrity leads to abnormal retinal lamination with a thickened, immature-appearing retina. This structural disorganization affects both photoreceptor and Muller cell architecture and may have both developmental (congenital) and degenerative components.
photoreceptor cell CL:0000210 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves photoreceptor cell (CL:0000210). CL:0000210 is a cell type from the Cell Ontology. Mueller cell CL:0000636 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Mueller cell (CL:0000636). CL:0000636 is a cell type from the Cell Ontology.
eye photoreceptor cell development GO:0042462 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated eye photoreceptor cell development (GO:0042462). GO:0042462 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Progressive photoreceptor degeneration and visual loss Structural disorganization renders photoreceptors vulnerable to progressive degeneration, with rate and pattern of loss varying by subtype and modifier context.
Show evidence (2 references)
PMID:12915475 SUPPORT Model Organism
"Photoreceptor degeneration is observed only within regions of retinal spotting, which is seen predominantly in the inferior nasal quadrant of the eye, and is caused by retinal folds and pseudorosettes."
Mouse model shows retinal disorganization with folds and pseudorosettes preceding degeneration.
PMID:36099972 SUPPORT Human Clinical
"The poor OCT lamination may have a degenerative component, as well as being congenital."
Clinical imaging suggests both developmental and degenerative contributions to retinal disorganization.
Progressive photoreceptor degeneration and visual loss
End-stage convergence across subtypes involves progressive rod and cone loss with declining visual acuity, visual field constriction, and extinguished electroretinogram. The rate of progression varies by subtype, with LCA/EOSRD showing earlier severe impairment than RP, and visual acuity survival analyses indicating an optimal intervention window in the first 2-3 decades.
retinal rod cell CL:0000604 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal rod cell (CL:0000604). CL:0000604 is a cell type from the Cell Ontology. retinal cone cell CL:0000573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal cone cell (CL:0000573). CL:0000573 is a cell type from the Cell Ontology.
photoreceptor cell maintenance GO:0045494 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased photoreceptor cell maintenance (GO:0045494). GO:0045494 is a biological process from the Gene Ontology. ↓ DECREASED neuron apoptotic process GO:0051402 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neuron apoptotic process (GO:0051402). GO:0051402 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Night blindness Progressive rod photoreceptor dysfunction produces night blindness in the RP branch of CRB1 disease.
Nystagmus Severe early-onset CRB1 retinal dysfunction can present with nystagmus.
Reduced visual acuity Progressive rod-cone degeneration leads to declining visual acuity across CRB1 retinal dystrophy subtypes.
Pigmentary retinopathy CRB1 retinal degeneration can produce peripheral pigment migration and nummular pigmentary changes.
Hypermetropia CRB1-associated retinal dystrophy is associated with hyperopia in a subset of patients.
Macular edema CRB1 retinal degeneration can include cystoid macular fluid collections and macular edema.
Macular dystrophy Progressive CRB1 retinal degeneration includes a macular-predominant dystrophy subtype.
Peripheral visual field constriction Progressive peripheral photoreceptor loss produces constriction of the peripheral visual field.
Show evidence (3 references)
PMID:36099972 SUPPORT Human Clinical
"Severe visual impairment was most frequent after 40 years of age for patients with RP and after 20 years of age for EOSRD/LCA."
Documents the differential timeline of severe visual impairment across CRB1 subtypes.
PMID:28341475 SUPPORT Human Clinical
"In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
Quantifies the progressive visual loss trajectory in CRB1-RP patients.
PMID:34320374 SUPPORT Human Clinical
"Microperimetry showed a significant decrease in retinal sensitivity during follow-up and may be a more sensitive progression marker."
Prospective natural history data confirms ongoing retinal sensitivity decline in CRB1 patients.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for CRB1 Retinal Dystrophies Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Eye 10
Night blindness VERY_FREQUENT Nyctalopia HP:0000662 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Night blindness, annotated with Nyctalopia (HP:0000662). HP:0000662 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"Night blindness was present in all patients but three, for whom a decrease of central vision and photophobia dominated."
Night blindness was present in the majority of CRB1-RP patients in this French cohort.
Nystagmus VERY_FREQUENT HP:0000639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nystagmus (HP:0000639). HP:0000639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"The onset of the disease occurs at birth and the characteristic features include non-recordable electroretinogram (ERG), nystagmus, sluggish or absent pupillary responses and oculo-digital reflexes"
Nystagmus is described as a characteristic LCA feature in CRB1-associated disease.
Reduced visual acuity VERY_FREQUENT HP:0007663 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced visual acuity (HP:0007663). HP:0007663 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36099972 SUPPORT Human Clinical
"Longitudinal analysis revealed a significant difference between baseline and follow-up best-corrected visual acuity in the 3 subcohorts."
Longitudinal data confirm progressive acuity decline across all CRB1 subtypes.
PMID:28341475 SUPPORT Human Clinical
"In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
Quantifies the rate and milestones of visual acuity decline in CRB1-RP.
Pigmentary retinopathy VERY_FREQUENT HP:0000580 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pigmentary retinopathy (HP:0000580). HP:0000580 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"7/11 had typical bone spicule-shaped pigment migration within the peripheral retina whereas 4/11 had widespread clumped pigmentary changes of nummular appearance at the level of the retinal pigment epithelium"
Documents two patterns of pigmentary change in CRB1-RP patients.
Hypermetropia FREQUENT HP:0000540 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypermetropia (HP:0000540). HP:0000540 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"Hyperopia was noted for 6/11 patients including three for whom spherical equivalent was equal or above +5 diopters."
Hyperopia was present in over half of the French CRB1-RP cohort.
Macular edema FREQUENT HP:0040049 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macular edema (HP:0040049). HP:0040049 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28341475 SUPPORT Human Clinical
"Cystoid fluid collections in the macula were found in 50% of RP patients."
Long-term follow-up documents high prevalence of macular cystic changes in CRB1-RP.
PMID:22065545 SUPPORT Human Clinical
"Six of the patients displayed cystoid macular edema whereas the other five had macular thinning with loss of the outer retinal layers"
Cystoid macular edema was present in approximately half of French CRB1 patients.
Macular dystrophy FREQUENT HP:0007754 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macular dystrophy (HP:0007754). HP:0007754 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36099972 SUPPORT Human Clinical
"24 with macular dystrophy (MD; 23%)"
Identifies macular dystrophy as a distinct clinical presentation in 23% of the cohort.
Keratoconus OCCASIONAL HP:0000563 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Keratoconus (HP:0000563). HP:0000563 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22065545 SUPPORT Human Clinical
"Predisposition of the CRB1 patients to keratoconus"
Literature review notes keratoconus as an associated feature of CRB1 mutations.
Peripheral visual field constriction FREQUENT Constriction of peripheral visual field HP:0001133 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral visual field constriction, annotated with Constriction of peripheral visual field (HP:0001133). HP:0001133 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28341475 SUPPORT Human Clinical
"The annual VF decline rate was 5% in patients from the genetic isolate, which was significantly faster than in non-GI patients (P < 0.05)."
Quantifies progressive visual field decline in CRB1-RP patients.
Undetectable electroretinogram FREQUENT HP:0000550 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Undetectable electroretinogram (HP:0000550). HP:0000550 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28341475 SUPPORT Human Clinical
"Full-field electroretinography responses were extinguished in 50% of patients, were pathologically attenuated without a documented rod or cone predominance in 30% of patients, and showed a rod-cone dysfunction pattern in 20% of RP patients."
Documents the spectrum of ERG findings in CRB1-RP from extinguished to attenuated responses.
Other 1
Retinal telangiectasia with exudation HP:0007763 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal telangiectasia (HP:0007763). HP:0007763 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22065545 SUPPORT Human Clinical
"retinal telangiectasia with exudation (also referred to as Coats-like vasculopathy)"
This review names retinal telangiectasia with exudation (Coats-like vasculopathy) as a specific fundus feature of CRB1-associated retinal dystrophy.
PMID:22065545 SUPPORT Human Clinical
"Retinal telangiectasia is a condition of abnormally permeable blood vessels, leading to exudation and retinal detachment"
Describes the vascular-leakage mechanism underlying the Coats-like exudative vasculopathy reported in CRB1 patients.
🧬

Genetic Associations

1
CRB1 (Causative)
Gene: CRB1 hgnc:2343 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CRB1 (hgnc:2343). hgnc:2343 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (7 references)
PMID:22065545 SUPPORT Human Clinical
"Mutations in the CRB1 gene are associated with variable phenotypes of severe retinal dystrophies, ranging from leber congenital amaurosis (LCA) to rod-cone dystrophy, also called retinitis pigmentosa (RP)."
Comprehensive review establishing CRB1 as the causal gene for the spectrum of retinal dystrophies.
PMID:22065545 SUPPORT Human Clinical
"This meta-analysis suggests that the differential phenotype of patients with CRB1 mutations is due to additional modifying factors rather than particular mutant allele combination."
Confirms CRB1 causality while noting phenotypic variability is driven by modifiers beyond allele type.
PMID:12915475 SUPPORT Model Organism
"Photoreceptor dysplasia and degeneration in Crb1 mutants strongly vary with genetic background, suggesting that the variability in phenotypes of human patients that carry mutations in CRB1 may be due to interactions with background modifiers in addition to allelic variations."
Mouse model confirms CRB1 as causal and supports the role of background modifiers in phenotypic variability.
+ 4 more references
📈

Progression

2
Early onset (LCA/EOSRD)
LCA8 Age: Birth to childhood
Congenital or infantile onset with non-recordable ERG. Severe visual impairment most frequent after age 20. Macular thickness decreases over time in most patients.
Show evidence (1 reference)
PMID:36099972 SUPPORT Human Clinical
"Severe visual impairment was most frequent after 40 years of age for patients with RP and after 20 years of age for EOSRD/LCA."
Documents the age-dependent timeline of severe visual impairment in the LCA subtype.
Childhood to adulthood (RP12)
RP12 Age: First two decades onward
Median symptom onset at age 4 years. Progressive decline with median ages for low vision at 18 years, severe visual impairment at 32 years, and blindness at 44 years. Visual acuity decline rate approximately 0.03 logMAR per year. Optimal intervention window for gene therapy within the first 2-3 decades.
Show evidence (2 references)
PMID:28341475 SUPPORT Human Clinical
"In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
Comprehensive long-term follow-up data quantifying CRB1-RP progression milestones.
PMID:28341475 SUPPORT Human Clinical
"Visual acuity survival analyses indicate that the optimal intervention window for subretinal gene therapy is within the first 2 to 3 decades of life."
Defines the therapeutic window based on visual acuity survival analysis.
{ }

Source YAML

click to show 
name: CRB1 Retinal Dystrophies
creation_date: "2026-04-04T12:00:00Z"
category: Mendelian
description: >-
  CRB1-associated retinal dystrophies are a spectrum of autosomal recessive
  inherited retinal diseases caused by biallelic pathogenic variants in CRB1,
  encoding Crumbs homolog 1. CRB1 is essential for external limiting membrane
  integrity and photoreceptor morphogenesis. Loss of CRB1 disrupts adherens
  junctions at the outer limiting membrane, leading to progressive photoreceptor
  degeneration. The clinical spectrum ranges from severe early-onset Leber
  congenital amaurosis (LCA8), through retinitis pigmentosa (RP12) with onset in
  the first two decades, to milder macular dystrophy. Distinctive features across
  the family include abnormally thickened and disorganized retinal lamination,
  nummular pigment deposits, preserved para-arteriolar retinal pigment epithelium
  (PPRPE), and Coats-like exudative vasculopathy. The differential phenotype is
  influenced by modifying factors in addition to the specific CRB1 allele
  combination, with null variants enriched in the EOSRD/LCA subtype. CRB1 is
  expressed in the retina as two isoforms in different cells - CRB1-A in Muller
  glia and CRB1-B in photoreceptors - and which of them a variant disrupts is a
  further determinant of where on the spectrum a patient falls.
disease_term:
  preferred_term: Leber congenital amaurosis 8
  term:
    id: MONDO:0013453
    label: Leber congenital amaurosis 8
synonyms:
- CRB1 retinopathy
- CRB1-related retinal dystrophy
- CRB1-associated retinal degeneration
parents:
- Ophthalmological Disease
- Retinal Dystrophy
- Inherited retinal dystrophy
has_subtypes:
- name: LCA8
  display_name: Leber Congenital Amaurosis 8 (EOSRD/LCA)
  subtype_term:
    preferred_term: Leber congenital amaurosis 8
    term:
      id: MONDO:0013453
      label: Leber congenital amaurosis 8
  subtype_frequency: "~52%"
  description: >-
    Severe early-onset branch with congenital or infantile visual impairment,
    nystagmus, and non-recordable electroretinogram. The EOSRD/LCA phenotype is
    significantly associated with null CRB1 variants. Severe visual impairment
    occurs after age 20 in most patients.
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
    explanation: This multicenter cohort shows EOSRD/LCA as the most frequent CRB1 subtype at 52%.
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EOSRD/LCA phenotype was significantly associated with null variants"
    explanation: Confirms the association of null CRB1 variants with the severe EOSRD/LCA phenotype.
- name: RP12
  display_name: Retinitis Pigmentosa 12
  subtype_term:
    preferred_term: retinitis pigmentosa 12
    term:
      id: MONDO:0010818
      label: retinitis pigmentosa 12
  subtype_frequency: "~25%"
  description: >-
    Rod-predominant retinal dystrophy branch with symptom onset in the first two
    decades (median age 4 years). Progressive peripheral field loss and night
    blindness, with severe visual impairment most frequent after age 40. A subset
    presents with mild, adult-onset disease.
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
    explanation: This cohort identifies RP as 25% of CRB1-associated retinal dystrophies.
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the RP patients, the median age at symptom onset was 4.0 years."
    explanation: Long-term follow-up study documents onset age and progressive course in CRB1-RP patients.
- name: Macular dystrophy
  display_name: CRB1-Associated Macular Dystrophy
  subtype_term:
    preferred_term: hereditary macular dystrophy
    term:
      id: MONDO:0020242
      label: hereditary macular dystrophy
  subtype_frequency: "~23%"
  description: >-
    Macular-predominant branch with central visual decline and relatively preserved
    peripheral vision. The 167_169 deletion was exclusively present in this cohort.
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "26 individuals were diagnosed with retinitis pigmentosa (RP; 25%), 54 with early-onset severe retinal dystrophy / Leber congenital amaurosis (EOSRD/LCA; 52%), and 24 with macular dystrophy (MD; 23%)"
    explanation: This multicenter cohort identifies macular dystrophy as 23% of CRB1-associated retinal dystrophies.
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "167_169 deletion was exclusively present in the MD cohort"
    explanation: Confirms a specific genotype-phenotype correlation for the macular dystrophy branch.
mechanistic_hypotheses:
- hypothesis_group_id: crb1a_muller_glial_primacy
  hypothesis_label: Muller-glial CRB1-A loss is the necessary lesion in human disease
  status: CANONICAL
  description: >-
    Human disease requires the Muller-glial isoform to be hit. No patient has yet
    been reported whose variants affect CRB1-B alone, and a cohort reappraisal
    that scored predicted isoform dosage per patient concluded that severity
    tracks with the CRB1-A lesion. On this model the outer limiting membrane
    fails from the glial side, and the photoreceptor isoform modifies the
    picture rather than initiating it.
  evidence:
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Crumbs homolog 1-A must be affected for disease manifestation, while sparing of CRB1-B leads to milder phenotypes."
    explanation: >-
      States the necessity claim directly, from the largest CRB1 genotype series
      to date.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans, the retinal degeneration appears early, and the phenotype is mainly driven by the Müller cell isoform A impairment."
    explanation: >-
      Independent cohort assigning the severity-determining role to the
      Muller-cell isoform in humans.
- hypothesis_group_id: crb1b_sparing_attenuates
  hypothesis_label: Preserved photoreceptor CRB1-B attenuates disease to macular-limited dystrophy
  status: EMERGING
  description: >-
    A second, contested claim: beyond requiring CRB1-A to be hit, the phenotype
    is graded by whether CRB1-B survives. Two recent cohorts find preserved
    wild-type CRB1-B enriched in macular-limited disease and CRB1-A-only variants
    associated with macular dystrophy. An earlier cohort that scored the same
    variable reached the opposite conclusion, so this is curated as emerging
    rather than settled - see the crb1_isoform_b_severity_conflict discussion.
  evidence:
  - reference: PMID:41358656
    reference_title: "Detailed Comparison Between Two Main Phenotypes of CRB1-Related Retinal Dystrophy, Pan-retinopathy and Maculopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proportion of patients harboring biallelic variants expressing wild-type CRB1-B was significantly higher in the maculopathy group (30.8%) than in the pan-retinopathy group (8.1%)."
    explanation: >-
      Direct cohort support for CRB1-B preservation grading the phenotype toward
      macular-limited disease.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations specific to CRB1-A, sparing CRB1-B were associated with MD."
    explanation: >-
      Replicates the association between CRB1-B sparing and macular dystrophy at
      n=389 across 50 cohorts.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The CRB1 isoform B has no impact on the severity of the phenotype as EORD, RP and macular dystrophy can occur regardless of the level of isoform B"
    explanation: >-
      A 50-patient cohort that scored predicted isoform-B dosage per patient
      found no severity effect, directly contradicting this hypothesis.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    CRB1-associated retinal dystrophies follow autosomal recessive inheritance.
    Biallelic pathogenic variants (two mutant alleles in trans) are required for
    disease manifestation. Over 150 CRB1 sequence variants have been reported in
    more than 240 patients.
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the CRB1 gene are associated with variable phenotypes of severe retinal dystrophies, ranging from leber congenital amaurosis (LCA) to rod-cone dystrophy, also called retinitis pigmentosa (RP)."
    explanation: This meta-analysis of CRB1 mutations confirms the autosomal recessive inheritance pattern across the retinal dystrophy spectrum.
pathophysiology:
- name: Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
  biological_scale: MOLECULAR
  description: >-
    CRB1 is transcribed in the retina as two major isoforms occupying different
    cells. The canonical 12-exon CRB1-A is expressed in Muller glia and is the
    predominant isoform during retinal development; the shorter CRB1-B is
    expressed in photoreceptors and is the more abundant isoform in the adult
    retina. Both reach the outer limiting membrane from opposite sides of the
    same junction. Because a variant's exon position determines which transcripts
    it disrupts, one gene produces cell-type-partitioned lesions rather than a
    single uniform loss: exon 6, 7 and 9 variants hit both isoforms, whereas exon
    2 variants such as c.498_506del p.(Ile167_Gly169del) affect CRB1-A only and
    leave CRB1-B intact. In the largest genotype series assembled to date every
    patient carried a variant affecting CRB1-A and none was CRB1-B-exclusive, so
    CRB1-A involvement appears necessary for disease.
  gene:
    preferred_term: CRB1
    modifier: DECREASED
    term:
      id: hgnc:2343
      label: CRB1
  cell_types:
  - preferred_term: Mueller cell
    term:
      id: CL:0000636
      label: Mueller cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  notes: >-
    No biological-process term is bound here on purpose. The two isoforms arise
    from distinct promoters rather than from regulated alternative splicing, so
    the GO splicing-regulation terms would misdescribe the mechanism, and GO has
    no term for isoform-partitioned expression across two cell types.
  downstream:
  - target: Loss of CRB1 at the outer limiting membrane
    causal_link_type: DIRECT
    hypothesis_groups:
    - crb1a_muller_glial_primacy
    description: >-
      Whichever isoform is disrupted, the lesion is delivered to the same
      structure: CRB1-A and CRB1-B are both present at the outer limiting
      membrane, on the Muller-cell and photoreceptor sides of the adherens
      junctions respectively.
    evidence:
    - reference: PMID:34884448
      reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These cell-surface proteins are both present at the level of the outer limiting membrane (OLM), which is formed by the adherens junctions between the adjacent Müller cells and photoreceptors, creating a distinct barrier between the neural retina and the inner/outer segments."
      explanation: >-
        Places both isoform products at the outer limiting membrane, which is why
        the isoform-partitioned lesion converges on a single structural node.
    - reference: PMID:34884448
      reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "All these models indicate that the lack of one or both isoforms induces OLM changes with loss of photoreceptor-Müller cell contacts combined with structural changes in both cell types."
      explanation: >-
        Isoform-selective mouse models show that losing either isoform alone is
        sufficient to produce outer limiting membrane changes.
  - target: Macular dystrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - crb1b_sparing_attenuates
    description: >-
      Proposed route to the macular-limited end of the spectrum: when the variant
      combination leaves photoreceptor CRB1-B intact, the retained adult-retina
      isoform is held to limit the lesion to the macula. The intermediate steps
      between preserved CRB1-B and macular-restricted degeneration are not known,
      and this edge belongs to an emerging hypothesis that one cohort contradicts.
    evidence:
    - reference: PMID:41358656
      reference_title: "Detailed Comparison Between Two Main Phenotypes of CRB1-Related Retinal Dystrophy, Pan-retinopathy and Maculopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The proportion of patients harboring biallelic variants expressing wild-type CRB1-B was significantly higher in the maculopathy group (30.8%) than in the pan-retinopathy group (8.1%)."
      explanation: >-
        Quantifies the enrichment of preserved CRB1-B in the macular-limited
        group relative to pan-retinopathy in a 75-patient cohort.
    - reference: PMID:41626423
      reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations specific to CRB1-A, sparing CRB1-B were associated with MD."
      explanation: >-
        Independently associates CRB1-A-only variants with the macular dystrophy
        phenotype in a 389-patient multi-cohort series.
  evidence:
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Crumbs homolog 1-A is primarily expressed in Müller cells and plays a vital role in retinal development, whereas CRB1-B, expressed in photoreceptors, helps maintain long-term retinal integrity in adult retinas."
    explanation: >-
      Establishes the cell-type assignment of the two isoforms and their
      differing developmental versus maintenance roles.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CRB1-A is localized to the apical tips of Müller cells and CRB1-B in the inner and outer segments with a gradient"
    explanation: >-
      Gives the subcellular localisation of each isoform, on either side of the
      outer limiting membrane.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CRB1-A is the predominant isoform during developmental stages. By contrast, CRB1-B is by far the most abundant isoform in the adult human, as well as murine retina."
    explanation: >-
      Supports the developmental versus adult division of labour between the two
      isoforms.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had variants affecting CRB1-A, with none exclusively affecting CRB1-B."
    explanation: >-
      Across 389 patients from 50 cohorts, CRB1-A involvement was universal,
      supporting it as a necessary condition for disease.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in exons 6, 7, and 9 were associated to LCA/EOSRD and RP phenotypes, whereas exon 2 variants were linked to MD."
    explanation: >-
      Shows that exon position, which determines isoform involvement, tracks with
      the clinical phenotype.
- name: Loss of CRB1 at the outer limiting membrane
  description: >-
    CRB1 localizes to the apical membrane of photoreceptors and Muller glial cells
    at the outer limiting membrane (OLM), where it maintains adherens junction
    integrity and cell polarity. Biallelic loss-of-function variants disrupt this
    structural scaffold, creating the shared proximal defect across the CRB1
    disease family.
  gene:
    preferred_term: CRB1
    modifier: DECREASED
    term:
      id: hgnc:2343
      label: CRB1
  cell_types:
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  - preferred_term: Mueller cell
    term:
      id: CL:0000636
      label: Mueller cell
  biological_processes:
  - preferred_term: adherens junction organization
    modifier: DECREASED
    term:
      id: GO:0034332
      label: adherens junction organization
  - preferred_term: establishment or maintenance of cell polarity
    modifier: DECREASED
    term:
      id: GO:0007163
      label: establishment or maintenance of cell polarity
  downstream:
  - target: Outer limiting membrane disruption and retinal disorganization
    description: >-
      Loss of CRB1 disrupts the OLM, leading to fragmented adherens junctions,
      retinal folds, and pseudorosettes. The resulting thickened and abnormally
      laminated retina is a hallmark of CRB1 retinopathy.
    evidence:
    - reference: PMID:12915475
      reference_title: "CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "staining for adherens junction proteins known to localize to the external limiting membrane, the equivalent of the zonula adherens in the mammalian retina, is discontinuous and fragmented"
      explanation: Mouse rd8 model directly shows OLM disruption from CRB1 loss.
  - target: Keratoconus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      CRB1-associated disease can include keratoconus, suggesting a corneal
      structural consequence in addition to retinal degeneration.
    evidence:
    - reference: PMID:22065545
      reference_title: "CRB1 mutations in inherited retinal dystrophies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Predisposition of the CRB1 patients to keratoconus"
      explanation: >-
        The CRB1 review notes keratoconus predisposition in affected patients,
        supporting this phenotype as linked to CRB1-associated disease.
  evidence:
  - reference: PMID:12915475
    reference_title: "CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Shortened photoreceptor inner and outer segments are observed as early as 2 weeks after birth, suggesting a developmental defect in these structures rather than a degenerative process."
    explanation: The rd8 mouse model demonstrates that CRB1 is essential for photoreceptor morphogenesis and OLM integrity.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CRB1 consists of 12 exons and exhibits alternative splicing at the 3' end, yielding two proteins of 1376 and 1406 amino acids"
    explanation: This review describes CRB1 protein structure including transmembrane and cytoplasmic domains critical for junction formation.
- name: Outer limiting membrane disruption and retinal disorganization
  description: >-
    Disrupted OLM integrity leads to abnormal retinal lamination with a thickened,
    immature-appearing retina. This structural disorganization affects both
    photoreceptor and Muller cell architecture and may have both developmental
    (congenital) and degenerative components.
  cell_types:
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  - preferred_term: Mueller cell
    term:
      id: CL:0000636
      label: Mueller cell
  biological_processes:
  - preferred_term: eye photoreceptor cell development
    modifier: DYSREGULATED
    term:
      id: GO:0042462
      label: eye photoreceptor cell development
  downstream:
  - target: Progressive photoreceptor degeneration and visual loss
    description: >-
      Structural disorganization renders photoreceptors vulnerable to progressive
      degeneration, with rate and pattern of loss varying by subtype and modifier
      context.
    evidence:
    - reference: PMID:28341475
      reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in the CRB1 gene are associated with a spectrum of progressive retinal degeneration."
      explanation: Long-term follow-up documents the progressive nature of photoreceptor loss in CRB1 disease.
  evidence:
  - reference: PMID:12915475
    reference_title: "CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Photoreceptor degeneration is observed only within regions of retinal spotting, which is seen predominantly in the inferior nasal quadrant of the eye, and is caused by retinal folds and pseudorosettes."
    explanation: Mouse model shows retinal disorganization with folds and pseudorosettes preceding degeneration.
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The poor OCT lamination may have a degenerative component, as well as being congenital."
    explanation: Clinical imaging suggests both developmental and degenerative contributions to retinal disorganization.
- name: Progressive photoreceptor degeneration and visual loss
  conforms_to: "photoreceptor_degeneration#Rod Photoreceptor Apoptosis"
  description: >-
    End-stage convergence across subtypes involves progressive rod and cone loss
    with declining visual acuity, visual field constriction, and extinguished
    electroretinogram. The rate of progression varies by subtype, with LCA/EOSRD
    showing earlier severe impairment than RP, and visual acuity survival analyses
    indicating an optimal intervention window in the first 2-3 decades.
  cell_types:
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    modifier: DECREASED
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
  - preferred_term: neuron apoptotic process
    modifier: INCREASED
    term:
      id: GO:0051402
      label: neuron apoptotic process
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe visual impairment was most frequent after 40 years of age for patients with RP and after 20 years of age for EOSRD/LCA."
    explanation: Documents the differential timeline of severe visual impairment across CRB1 subtypes.
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
    explanation: Quantifies the progressive visual loss trajectory in CRB1-RP patients.
  - reference: PMID:34320374
    reference_title: "CRB1-Associated Retinal Dystrophies: A Prospective Natural History Study in Anticipation of Future Clinical Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microperimetry showed a significant decrease in retinal sensitivity during follow-up and may be a more sensitive progression marker."
    explanation: Prospective natural history data confirms ongoing retinal sensitivity decline in CRB1 patients.
  downstream:
  - target: Night blindness
    causal_link_type: DIRECT
    description: >-
      Progressive rod photoreceptor dysfunction produces night blindness in the
      RP branch of CRB1 disease.
    evidence:
    - reference: PMID:22065545
      reference_title: "CRB1 mutations in inherited retinal dystrophies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Night blindness was present in all patients but three, for whom a decrease of central vision and photophobia dominated."
      explanation: >-
        The French CRB1 cohort supports night blindness as a common downstream
        manifestation of CRB1-related retinal degeneration.
  - target: Nystagmus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Early severe visual impairment
    description: >-
      Severe early-onset CRB1 retinal dysfunction can present with nystagmus.
    evidence:
    - reference: PMID:22065545
      reference_title: "CRB1 mutations in inherited retinal dystrophies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The onset of the disease occurs at birth and the characteristic features include non-recordable electroretinogram (ERG), nystagmus, sluggish or absent pupillary responses and oculo-digital reflexes"
      explanation: >-
        Review evidence supports nystagmus as a characteristic early severe
        CRB1-associated retinal dystrophy feature.
  - target: Reduced visual acuity
    causal_link_type: DIRECT
    description: >-
      Progressive rod-cone degeneration leads to declining visual acuity across
      CRB1 retinal dystrophy subtypes.
    evidence:
    - reference: PMID:36099972
      reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Longitudinal analysis revealed a significant difference between baseline and follow-up best-corrected visual acuity in the 3 subcohorts."
      explanation: >-
        Longitudinal cohort evidence links CRB1 disease progression to declining
        best-corrected visual acuity.
  - target: Pigmentary retinopathy
    causal_link_type: DIRECT
    description: >-
      CRB1 retinal degeneration can produce peripheral pigment migration and
      nummular pigmentary changes.
    evidence:
    - reference: PMID:22065545
      reference_title: "CRB1 mutations in inherited retinal dystrophies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "7/11 had typical bone spicule-shaped pigment migration within the peripheral retina whereas 4/11 had widespread clumped pigmentary changes of nummular appearance at the level of the retinal pigment epithelium"
      explanation: >-
        The CRB1 cohort documents pigmentary retinopathy patterns in affected
        patients.
  - target: Hypermetropia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      CRB1-associated retinal dystrophy is associated with hyperopia in a subset
      of patients.
    evidence:
    - reference: PMID:22065545
      reference_title: "CRB1 mutations in inherited retinal dystrophies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hyperopia was noted for 6/11 patients including three for whom spherical equivalent was equal or above +5 diopters."
      explanation: >-
        The CRB1 cohort supports hyperopia/hypermetropia as a downstream ocular
        manifestation.
  - target: Macular edema
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Retinal cystoid fluid collections
    description: >-
      CRB1 retinal degeneration can include cystoid macular fluid collections
      and macular edema.
    evidence:
    - reference: PMID:28341475
      reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cystoid fluid collections in the macula were found in 50% of RP patients."
      explanation: >-
        Long-term follow-up supports cystoid macular edema as a downstream
        manifestation in CRB1-RP.
  - target: Macular dystrophy
    causal_link_type: DIRECT
    description: >-
      Progressive CRB1 retinal degeneration includes a macular-predominant
      dystrophy subtype.
    evidence:
    - reference: PMID:36099972
      reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "24 with macular dystrophy (MD; 23%)"
      explanation: >-
        Multicenter cohort evidence identifies macular dystrophy as a CRB1
        retinal dystrophy presentation.
  - target: Peripheral visual field constriction
    causal_link_type: DIRECT
    description: >-
      Progressive peripheral photoreceptor loss produces constriction of the
      peripheral visual field.
    evidence:
    - reference: PMID:28341475
      reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The annual VF decline rate was 5% in patients from the genetic isolate, which was significantly faster than in non-GI patients (P < 0.05)."
      explanation: >-
        Long-term follow-up directly supports progressive visual field decline
        in CRB1-RP.
phenotypes:
- category: Ophthalmic
  name: Night blindness
  frequency: VERY_FREQUENT
  subtype: RP12
  description: >-
    Night blindness is a common presenting symptom in the RP branch, reflecting
    early rod photoreceptor dysfunction.
  phenotype_term:
    preferred_term: Night blindness
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Night blindness was present in all patients but three, for whom a decrease of central vision and photophobia dominated."
    explanation: Night blindness was present in the majority of CRB1-RP patients in this French cohort.
- category: Ophthalmic
  name: Nystagmus
  frequency: VERY_FREQUENT
  subtype: LCA8
  description: >-
    Nystagmus is a characteristic sign of the severe EOSRD/LCA branch, reflecting
    early and severe visual impairment from birth or infancy.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The onset of the disease occurs at birth and the characteristic features include non-recordable electroretinogram (ERG), nystagmus, sluggish or absent pupillary responses and oculo-digital reflexes"
    explanation: Nystagmus is described as a characteristic LCA feature in CRB1-associated disease.
- category: Ophthalmic
  name: Reduced visual acuity
  frequency: VERY_FREQUENT
  description: >-
    Progressive decline of visual acuity across all subtypes, with severity and
    rate depending on the CRB1 subtype. EOSRD/LCA patients experience earlier
    severe impairment than RP patients.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Longitudinal analysis revealed a significant difference between baseline and follow-up best-corrected visual acuity in the 3 subcohorts."
    explanation: Longitudinal data confirm progressive acuity decline across all CRB1 subtypes.
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
    explanation: Quantifies the rate and milestones of visual acuity decline in CRB1-RP.
- category: Ophthalmic
  name: Pigmentary retinopathy
  frequency: VERY_FREQUENT
  subtype: RP12
  description: >-
    Pigmentary changes in CRB1-RP include either typical bone-spicule pigment
    migration or distinctive nummular (clumped) pigment deposits. Preserved
    para-arteriolar retinal pigment epithelium (PPRPE) is a hallmark but not
    universal finding.
  phenotype_term:
    preferred_term: Pigmentary retinopathy
    term:
      id: HP:0000580
      label: Pigmentary retinopathy
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "7/11 had typical bone spicule-shaped pigment migration within the peripheral retina whereas 4/11 had widespread clumped pigmentary changes of nummular appearance at the level of the retinal pigment epithelium"
    explanation: Documents two patterns of pigmentary change in CRB1-RP patients.
- category: Ophthalmic
  name: Hypermetropia
  frequency: FREQUENT
  description: >-
    Hyperopia (farsightedness) is noted in a substantial proportion of CRB1
    patients, consistent with the shortened axial length sometimes associated with
    retinal dystrophies.
  phenotype_term:
    preferred_term: Hypermetropia
    term:
      id: HP:0000540
      label: Hypermetropia
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperopia was noted for 6/11 patients including three for whom spherical equivalent was equal or above +5 diopters."
    explanation: Hyperopia was present in over half of the French CRB1-RP cohort.
- category: Ophthalmic
  name: Macular edema
  frequency: FREQUENT
  description: >-
    Cystoid macular edema is found in approximately 50% of CRB1-RP patients, a
    higher prevalence than in overall RP, possibly related to vascular
    abnormalities or abnormal retinal lamination.
  phenotype_term:
    preferred_term: Macular edema
    term:
      id: HP:0040049
      label: Macular edema
  evidence:
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cystoid fluid collections in the macula were found in 50% of RP patients."
    explanation: Long-term follow-up documents high prevalence of macular cystic changes in CRB1-RP.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six of the patients displayed cystoid macular edema whereas the other five had macular thinning with loss of the outer retinal layers"
    explanation: Cystoid macular edema was present in approximately half of French CRB1 patients.
- category: Ophthalmic
  name: Macular dystrophy
  frequency: FREQUENT
  subtype: Macular dystrophy
  description: >-
    Central macular involvement with progressive macular atrophy, characterizing
    the macular dystrophy subtype but also occurring across other CRB1 subtypes.
  phenotype_term:
    preferred_term: Macular dystrophy
    term:
      id: HP:0007754
      label: Macular dystrophy
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "24 with macular dystrophy (MD; 23%)"
    explanation: Identifies macular dystrophy as a distinct clinical presentation in 23% of the cohort.
- category: Ophthalmic
  name: Keratoconus
  frequency: OCCASIONAL
  description: >-
    Keratoconus has been reported in CRB1 patients, suggesting CRB1 may have a
    role in corneal structural integrity beyond its retinal function.
  phenotype_term:
    preferred_term: Keratoconus
    term:
      id: HP:0000563
      label: Keratoconus
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Predisposition of the CRB1 patients to keratoconus"
    explanation: Literature review notes keratoconus as an associated feature of CRB1 mutations.
- category: Ophthalmic
  name: Retinal telangiectasia with exudation
  description: >-
    Retinal telangiectasia with exudation, referred to as Coats-like vasculopathy,
    is a distinctive but non-universal fundus feature of CRB1-associated retinal
    dystrophy. Abnormally permeable, dilated intraretinal vessels leak serous fluid
    and lipid and, in severe cases, can progress to exudative retinal detachment.
    It is most characteristic of the severe early-onset end of the spectrum and was
    absent in some milder adult-onset RP cohorts.
  phenotype_term:
    preferred_term: Retinal telangiectasia
    term:
      id: HP:0007763
      label: Retinal telangiectasia
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "retinal telangiectasia with exudation (also referred to as Coats-like vasculopathy)"
    explanation: This review names retinal telangiectasia with exudation (Coats-like vasculopathy) as a specific fundus feature of CRB1-associated retinal dystrophy.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retinal telangiectasia is a condition of abnormally permeable blood vessels, leading to exudation and retinal detachment"
    explanation: Describes the vascular-leakage mechanism underlying the Coats-like exudative vasculopathy reported in CRB1 patients.
- category: Ophthalmic
  name: Peripheral visual field constriction
  frequency: FREQUENT
  subtype: RP12
  description: >-
    Progressive constriction of the peripheral visual field reflects ongoing rod
    photoreceptor loss in the RP branch.
  phenotype_term:
    preferred_term: Peripheral visual field constriction
    term:
      id: HP:0001133
      label: Constriction of peripheral visual field
  evidence:
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The annual VF decline rate was 5% in patients from the genetic isolate, which was significantly faster than in non-GI patients (P < 0.05)."
    explanation: Quantifies progressive visual field decline in CRB1-RP patients.
- category: Ophthalmic
  name: Undetectable electroretinogram
  frequency: FREQUENT
  description: >-
    Non-recordable or severely attenuated electroretinogram is characteristic of
    advanced CRB1 disease, present from birth in LCA and developing progressively
    in RP.
  phenotype_term:
    preferred_term: Undetectable electroretinogram
    term:
      id: HP:0000550
      label: Undetectable electroretinogram
  evidence:
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Full-field electroretinography responses were extinguished in 50% of patients, were pathologically attenuated without a documented rod or cone predominance in 30% of patients, and showed a rod-cone dysfunction pattern in 20% of RP patients."
    explanation: Documents the spectrum of ERG findings in CRB1-RP from extinguished to attenuated responses.
  reports_on:
  - target: Progressive photoreceptor degeneration and visual loss
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Severe CRB1 photoreceptor dysfunction can extinguish electroretinogram
      responses.
    evidence:
    - reference: PMID:28341475
      reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Full-field electroretinography responses were extinguished in 50% of patients, were pathologically attenuated without a documented rod or cone predominance in 30% of patients, and showed a rod-cone dysfunction pattern in 20% of RP patients."
      explanation: >-
        Long-term follow-up supports extinguished ERG responses as a downstream
        functional consequence of CRB1 retinal degeneration.
progression:
- phase: Early onset (LCA/EOSRD)
  subtype: LCA8
  age_range: Birth to childhood
  notes: >-
    Congenital or infantile onset with non-recordable ERG. Severe visual
    impairment most frequent after age 20. Macular thickness decreases over time
    in most patients.
  evidence:
  - reference: PMID:36099972
    reference_title: "CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe visual impairment was most frequent after 40 years of age for patients with RP and after 20 years of age for EOSRD/LCA."
    explanation: Documents the age-dependent timeline of severe visual impairment in the LCA subtype.
- phase: Childhood to adulthood (RP12)
  subtype: RP12
  age_range: First two decades onward
  notes: >-
    Median symptom onset at age 4 years. Progressive decline with median ages for
    low vision at 18 years, severe visual impairment at 32 years, and blindness at
    44 years. Visual acuity decline rate approximately 0.03 logMAR per year.
    Optimal intervention window for gene therapy within the first 2-3 decades.
  evidence:
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the RP group, median ages for reaching low vision, severe visual impairment, and blindness were 18, 32, and 44 years, respectively, with a visual acuity decline rate of 0.03 logarithm of the minimum angle of resolution per year."
    explanation: Comprehensive long-term follow-up data quantifying CRB1-RP progression milestones.
  - reference: PMID:28341475
    reference_title: "Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual acuity survival analyses indicate that the optimal intervention window for subretinal gene therapy is within the first 2 to 3 decades of life."
    explanation: Defines the therapeutic window based on visual acuity survival analysis.
genetic:
- name: CRB1
  features: >-
    CRB1 encodes Crumbs homolog 1, a transmembrane protein with 19 EGF-like
    domains, 3 laminin A globular-like domains, and a cytoplasmic domain with FERM
    and PDZ binding motifs. Over 150 pathogenic variants have been reported, with
    missense mutations constituting 66% and exons 7 and 9 being most frequently
    mutated. The p.Cys948Tyr variant in exon 9 is the most common (24% of known
    CRB1 mutations). Null variants are enriched in EOSRD/LCA, but genotype-phenotype
    correlation is limited by modifier effects. Exon position matters because it
    determines which retinal isoforms a variant disrupts: exon 6, 7 and 9 variants
    affect both CRB1-A and CRB1-B and track with LCA/EOSRD and RP, whereas exon 2
    variants - notably the in-frame deletion c.498_506del p.(Ile167_Gly169del) -
    affect CRB1-A only and track with macular dystrophy. The exon-7 missense
    c.2506C>A p.(Pro836Thr) is the common variant of Black African ancestry, at
    0.329% allele frequency in African populations in gnomAD v4.1.0.
  gene_term:
    preferred_term: CRB1
    term:
      id: hgnc:2343
      label: CRB1
  association: Causative
  evidence:
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the CRB1 gene are associated with variable phenotypes of severe retinal dystrophies, ranging from leber congenital amaurosis (LCA) to rod-cone dystrophy, also called retinitis pigmentosa (RP)."
    explanation: Comprehensive review establishing CRB1 as the causal gene for the spectrum of retinal dystrophies.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This meta-analysis suggests that the differential phenotype of patients with CRB1 mutations is due to additional modifying factors rather than particular mutant allele combination."
    explanation: Confirms CRB1 causality while noting phenotypic variability is driven by modifiers beyond allele type.
  - reference: PMID:12915475
    reference_title: "CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Photoreceptor dysplasia and degeneration in Crb1 mutants strongly vary with genetic background, suggesting that the variability in phenotypes of human patients that carry mutations in CRB1 may be due to interactions with background modifiers in addition to allelic variations."
    explanation: Mouse model confirms CRB1 as causal and supports the role of background modifiers in phenotypic variability.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequently occurring of the known mutations is the p.Cys948Tyr in exon 9 (96 alleles reported, 24% of known CRB1 mutations)"
    explanation: Directly supports p.Cys948Tyr in exon 9 as the single most common CRB1 variant, accounting for 24% of known mutations.
  - reference: PMID:22065545
    reference_title: "CRB1 mutations in inherited retinal dystrophies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Missense mutations constitute 66% of all known mutations, the remaining being frameshift, truncation and splice site mutations."
    explanation: Supports the mutation-class distribution stated in the features summary, with missense variants constituting 66% of known CRB1 mutations.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in exons 6, 7, and 9 were associated to LCA/EOSRD and RP phenotypes, whereas exon 2 variants were linked to MD."
    explanation: >-
      Supports the exon-position-to-phenotype correlation stated in the features
      summary, from 389 patients across 50 cohorts.
  - reference: PMID:40590804
    reference_title: "A Phenotypic Study of CRB1 Retinopathy Secondary to the Variant p.(Pro836Thr) Prevalent in Those of Black African Ancestry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In African populations, this variant has an allele frequency of 0.329% (gnomAD v4.1.0)."
    explanation: >-
      Directly supports the stated African-population allele frequency for
      p.(Pro836Thr).
discussions:
- discussion_id: crb1_isoform_b_severity_conflict
  prompt: >-
    Does preserved photoreceptor CRB1-B actually attenuate CRB1 retinopathy, or
    is the association with macular-limited disease carried entirely by which
    CRB1-A variants happen to spare it?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#crb1b_sparing_attenuates
  - pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
  rationale: >-
    Three cohorts have scored the same variable and disagree. Two recent series
    (n=75 and n=389) find wild-type CRB1-B enriched in macular-limited disease
    and CRB1-A-only variants associated with macular dystrophy. An earlier series
    (n=50) scored predicted isoform dosage patient by patient and found the
    opposite: it reports patients with fully preserved isoform B who nonetheless
    had early-onset retinal dystrophy, and patients with the macular c.498_506del
    variant who developed macular dystrophy irrespective of isoform-B status.
    The disagreement is not merely one of cohort size, because the alternative
    reading is confounding rather than noise: the exon-2 variants that spare
    CRB1-B are also the mildest CRB1-A lesions, so isoform-B preservation may be
    a marker of a mild CRB1-A allele rather than a protective factor in its own
    right. All three cohorts report predicted, not measured, isoform dosage.
  evidence:
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, all patients with the specific c.498_506del macular variant developed a macular dystrophy regardless of the impact on isoform B."
    explanation: >-
      The observation on which the dissenting cohort rests: within carriers of
      the macular variant, isoform-B status made no difference.
  - reference: PMID:41358656
    reference_title: "Detailed Comparison Between Two Main Phenotypes of CRB1-Related Retinal Dystrophy, Pan-retinopathy and Maculopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with biallelic loss-of-function variants were significantly more prevalent in the pan-retinopathy group (40.3%) than in the maculopathy group (7.1%) (P = 0.03)."
    explanation: >-
      Shows that allele severity itself also separates the two groups, which is
      the confound the isoform claim has to be disentangled from.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Macular dystrophy was not exclusively seen because of preservation of CRB1-B on one allele, as it also appeared in patients with variants affecting CRB1-B in both alleles."
    explanation: >-
      States the confound in the source's own words: the macular phenotype
      arises even when CRB1-B is disrupted on both alleles, so CRB1-B
      preservation is not necessary for it. The same paper attributes those
      cases to CRB1-A missense variants predicted to have minimal structural
      impact, which is the mild-allele reading rather than a protective
      isoform effect.
  proposed_experiments:
  - experiment_id: crb1_isoform_dosage_organoid_series
    name: Measured isoform dosage in patient iPSC-derived retinal organoids stratified by phenotype
    description: >-
      Derive retinal organoids from patients matched for predicted CRB1-A lesion
      severity but differing in whether CRB1-B is spared, and quantify CRB1-A and
      CRB1-B transcript and protein directly instead of predicting them from exon
      position. Score outer limiting membrane integrity and photoreceptor
      lamination.
    would_support:
    - pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
    supporting_outcome:
    - >-
      Among patients matched on CRB1-A lesion severity, those retaining measured
      CRB1-B protein show better preserved outer limiting membrane and lamination
      than those who do not.
    refuting_outcome:
    - >-
      Organoid phenotype tracks with measured CRB1-A dosage alone, with no
      residual effect of CRB1-B once CRB1-A severity is matched.
- discussion_id: crb1_isoform_hierarchy_mouse_versus_human
  prompt: >-
    Mouse work makes Crb1-B the essential isoform while human cohorts make CRB1-A
    the essential one - is that a real species difference, or an artefact of what
    human sequencing panels can see?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
  - mechanistic_hypotheses#crb1a_muller_glial_primacy
  rationale: >-
    Isoform-selective mouse alleles put Crb1-B in the primary role: retinal
    anomalies develop in the mouse even when Crb1-A is normal. Human cohorts
    invert this, reporting that CRB1-A is universally affected and appears to
    drive severity. The mismatch cannot currently be resolved on the human side,
    because diagnostic sequencing panels do not cover the promoter and terminal
    exons unique to the CRB1-B transcript, so a human counterpart of the
    isoform-B-selective mouse genotype would not be detected even if it existed.
    The human evidence for CRB1-A primacy is therefore ascertainment-limited, and
    the apparent species difference should not be treated as established until
    panels are redesigned. This directly conditions how mouse rescue data should
    be read when selecting an isoform for gene-supplementation therapy.
  evidence:
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Based on the characterization of the previously known and novel models, Ray et al. stated that, in mice, Crb1-B is essential and predominant, as retinal anomalies can develop even when Crb1-A is strictly normal."
    explanation: >-
      States the mouse hierarchy that the human data invert.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A human phenotype equivalent to the Crb1delB/null or Crb1delB/delB mouse models has never been reported"
    explanation: >-
      The specific human observation that is missing, and which the panel gap
      explains.
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had variants affecting CRB1-A, with none exclusively affecting CRB1-B."
    explanation: >-
      The human observation whose interpretation is at stake: universal CRB1-A
      involvement is consistent both with CRB1-A necessity and with CRB1-B-only
      genotypes being invisible to the assay.
  proposed_experiments:
  - experiment_id: crb1b_specific_region_resequencing
    name: Resequence CRB1-B-specific promoter and terminal exons in unsolved and monoallelic CRB1 cases
    description: >-
      Extend retinal gene panels to the CRB1-B-specific promoter and 5-prime and
      3-prime exons, then re-screen patients carrying a single CRB1 variant and
      patients with unsolved inherited retinal dystrophy.
    would_refute:
    - mechanistic_hypotheses#crb1a_muller_glial_primacy
    supporting_outcome:
    - >-
      Patients with biallelic variants confined to CRB1-B-specific regions are
      identified, showing the human hierarchy was an ascertainment artefact.
    refuting_outcome:
    - >-
      No biallelic CRB1-B-exclusive genotypes are found after adequate coverage,
      strengthening CRB1-A involvement as a genuine necessary condition.
- discussion_id: crb1_macular_dystrophy_mechanism_unmodelled
  prompt: >-
    By what mechanism do CRB1-A-specific variants such as c.498_506del produce
    macular-restricted rather than generalised retinal disease?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - has_subtypes#Macular dystrophy
  - pathophysiology#Isoform-partitioned loss of CRB1-A in Muller glia and CRB1-B in photoreceptors
  rationale: >-
    The genotype-phenotype association is now replicated and strong, but no
    mechanism connects it to a macular topography. The gap is a model gap rather
    than a data gap: there is no mouse carrying the equivalent in-frame deletion
    and, at the time of the largest series, no macular-dystrophy CRB1 induced
    pluripotent stem cell line was available. Structural prediction suggests the
    deletion destabilises two adjacent EGF-like modules, but that does not
    explain why the consequence is confined to the macula.
  evidence:
  - reference: PMID:41626423
    reference_title: "Novel Genotype-Phenotype Correlations in CRB1-Retinopathies: Insights from Isoforms and Protein Domains Linked to Disease Severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the precise mechanism by which these variants lead to MD remains unclear, largely because of the absence of corresponding mouse models or MD-CRB1 induced pluripotent stem cell lines for further investigation."
    explanation: >-
      States the gap and its cause - the absent model systems - in the authors'
      own words.
  - reference: PMID:34884448
    reference_title: "CRB1-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With the lack of a corresponding mouse model, the mechanism of this variant is not clearly known."
    explanation: >-
      The same gap identified independently four years earlier for the
      c.498_506del variant specifically.
- discussion_id: crb1_subtype_axis_under_review
  prompt: >-
    Should this entry keep the flat LCA8 / RP12 / macular dystrophy split, or
    move to the pan-retinopathy versus maculopathy axis used by the newer
    literature?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - has_subtypes#
  rationale: >-
    The three subtypes here follow the phenotypic diagnoses assigned in a single
    104-patient cohort, and all three subtype frequencies come from one sentence
    in it. Two later series reorganise the same disease along a different axis:
    a 75-patient cohort treats pan-retinopathy and maculopathy as the two primary
    phenotypes and calls them distinct entities, which collapses LCA8 and RP12
    into severity poles of one branch while setting maculopathy apart on genetic
    grounds; a 389-patient reclassification under standardised criteria adds
    cone-rod dystrophy as a fourth phenotype. A counterweight is that in one
    p.(Pro836Thr) series, imaging that looked macula-confined sat on top of
    generalised photoreceptor dysfunction on electrophysiology, so a
    structurally-defined maculopathy category may not be as clean as it appears.
    Restructuring has_subtypes would also strand the LCA8 and RP12 MONDO
    groundings, which are the two mappings in this entry that are unambiguously
    correct. The decision, together with the entry-level disease_term question,
    is reserved for the maintainer in issue 8997 and is deliberately not taken
    here; this discussion records the evidence so the choice is not re-derived
    from scratch.
  evidence:
  - reference: PMID:41358656
    reference_title: "Detailed Comparison Between Two Main Phenotypes of CRB1-Related Retinal Dystrophy, Pan-retinopathy and Maculopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study establishes CRB1-associated pan-retinopathy and maculopathy as clinically and genetically distinct entities."
    explanation: >-
      The competing two-way nosology, asserted on combined clinical and genetic
      grounds.
  - reference: PMID:40590804
    reference_title: "A Phenotypic Study of CRB1 Retinopathy Secondary to the Variant p.(Pro836Thr) Prevalent in Those of Black African Ancestry."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Although retinal imaging may show alterations confined to the macular region, electrophysiology in this series indicates generalized cone and rod photoreceptor dysfunction."
    explanation: >-
      Cautions against reifying a maculopathy category from imaging, since
      function was generalised in the same patients.
review_notes: >-
  Modeled as a shared-mechanism umbrella because CRB1 loss-of-function produces a
  continuum of retinal dystrophy severity unified by outer limiting membrane
  disruption and abnormal retinal lamination. No broader CRB1-specific MONDO class
  exists, so MONDO:0013453 (Leber congenital amaurosis 8) is used as the root
  disease_term with preferred_term matching the MONDO label; the umbrella concept
  name lives in the entry name field. RP12 (MONDO:0010818) and hereditary macular
  dystrophy (MONDO:0020242) are subtypes. Pigmented paravenous atrophy association
  with CRB1 has limited evidence and questionable pathogenicity and is noted but
  not elevated to a subtype.

  Two mapping decisions recorded here are contested in issue 8997 and are left
  untouched pending a maintainer ruling, not endorsed by this pass. First, the
  entry-level disease_term is MONDO:0013453, which is also the LCA8 subtype term,
  so the spectrum is grounded to one branch of itself; the three subtype terms
  sit under three different MONDO parents, so no subtype term can serve as the
  spectrum root, and MONDO has no CRB1-spectrum class. Second, the macular
  dystrophy subtype is grounded to the generic, non-gene-restricted
  MONDO:0020242. Regrounding, unsetting disease_term, or restructuring
  has_subtypes along the pan-retinopathy versus maculopathy axis are all
  deferred; see the crb1_subtype_axis_under_review discussion for the evidence
  bearing on the third.

  The isoform layer added in 2026 is deliberately modelled as one upstream
  pathophysiology node plus two mechanistic_hypotheses rather than folded into
  the existing outer-limiting-membrane node, because the two claims have very
  different support: CRB1-A involvement being necessary is unanimous across
  cohorts, whereas CRB1-B sparing being protective is contradicted by one of the
  three cohorts that measured it.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 18 citations 2026-04-04T12:49:28.427535

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: CRB1 Retinal Dystrophies
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on CRB1 Retinal Dystrophies covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: CRB1 Retinal Dystrophies (Mendelian IRD)

Scope note

“CRB1 retinal dystrophies” refers to the spectrum of inherited retinal diseases (IRDs) caused by biallelic pathogenic variants in CRB1, including early-onset severe retinal dystrophy/Leber congenital amaurosis (EOSRD/LCA8), retinitis pigmentosa (RP12), and CRB1-associated macular dystrophy/maculopathy, with additional less common phenotypes such as cone–rod dystrophy and foveal retinoschisis/schitic maculopathy. (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11, roshandel2021multimodalretinalimaging pages 1-2)

1. Disease information

1.1 Concise overview

CRB1-retinopathies are autosomal recessive IRDs characterized by high phenotypic heterogeneity across a spectrum from severe childhood-onset retinal dystrophy (EOSRD/LCA) to later-onset RP and macula-centered dystrophies, often with distinctive fundus and OCT features (e.g., preserved para-arteriolar RPE, abnormal retinal lamination/thickening, nummular pigmentation, cystic/schitic maculopathy). (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11, roshandel2021multimodalretinalimaging pages 1-2)

1.2 Key identifiers (available from retrieved sources)

  • Gene: CRB1 (Crumbs homolog 1) (daher2024genotypephenotypeassociationsin pages 1-2)
  • OMIM (disease associations mentioned in retrieved sources):
  • Leber congenital amaurosis-8 (LCA8): OMIM #613835 (mentioned in CRB1 retinopathy imaging/natural history context) (roshandel2021multimodalretinalimaging pages 1-2)
  • Retinitis pigmentosa 12 (RP12): OMIM 600105 (noted in CRB1 disease context in older CRB1 literature excerpt) (varela2023crb1associatedretinaldystrophies pages 1-2)

MONDO ID / Orphanet / ICD-10/ICD-11 / MeSH: Not retrievable from the current tool state (no OMIM/Orphanet/MeSH/ICD source pages were available in the retrieved full texts). This section is therefore partial and should be completed by querying OMIM/Orphanet/MONDO directly.

1.3 Common synonyms / alternative names (as used in the literature)

  • “CRB1-associated retinal dystrophies” (varela2023crb1associatedretinaldystrophies pages 1-2)
  • “CRB1-associated retinopathies” (roshandel2021multimodalretinalimaging pages 1-2)
  • “CRB1-retinopathies” (rodriguezmartinez2025expandingtheclinical pages 1-2)
  • Phenotype labels used: EOSRD, LCA, RP, macular dystrophy/maculopathy, cone–rod dystrophy, rod–cone dystrophy, foveal retinoschisis, cystic/schitic maculopathy, and a newly described asymptomatic fenestrated slit maculopathy (AFSM) (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2)

1.4 Evidence source type

The current report uses aggregated disease-level resources from primary cohorts and systematic reviews/meta-analysis, not EHR-only evidence. The two highest-weight sources are a multicenter retrospective cohort (104 patients) and a systematic review/meta-analysis (439 patients). (varela2023crb1associatedretinaldystrophies pages 1-2, daher2024genotypephenotypeassociationsin pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in CRB1, which encodes a component of the Crumbs apical polarity complex at the retinal outer limiting membrane (OLM), functioning in apical–basal polarity and adhesion at the photoreceptor–Müller glia interface. (stehle2024humancrb1and pages 1-2, buck2023crb1isrequired pages 1-3)

Direct abstract-supported statement (mechanism framing): * Owen et al. (2023) describe the crumbs complex as having a “crucial role in apical–basal epithelial polarity, cellular adhesion, and morphogenesis,” and note that “Homozygous variants in human CRB1 result in autosomal recessive Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP).” (owen2023lossofthe pages 1-2)

2.2 Risk factors

  • Genetic risk: presence of biallelic CRB1 pathogenic variants; severity tends to relate to allelic class (null vs hypomorphic). (varela2023crb1associatedretinaldystrophies pages 9-11, daher2024genotypephenotypeassociationsin pages 1-2)

  • In a large multicenter cohort, double-null genotypes occurred only in EOSRD/LCA, supporting a genotype–severity relationship. (varela2023crb1associatedretinaldystrophies pages 9-11)

  • Non-genetic/environmental risk factors: No established, disease-specific environmental risk factors were identified in the retrieved evidence.

2.3 Protective factors

  • The retrieved evidence does not identify validated genetic or environmental protective factors for CRB1-retinopathies.

2.4 Gene–environment interactions

No CRB1-specific gene–environment interaction evidence was retrievable from the current document set.

3. Phenotypes

3.1 Phenotype spectrum and frequencies (recent aggregated human data)

A multicenter cohort of molecularly confirmed CRB1-retinopathy (n=104) reported three main clinical categories: EOSRD/LCA (≈52%), RP (≈25%), and macular dystrophy (≈23%), with additional phenotypes including cone–rod dystrophy and foveal retinoschisis/maculopathy variants. (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11)

A meta-analysis of published bi-allelic CRB1 cases (96 studies; 439 patients) reported systematic genotype–phenotype signals (e.g., missense vs nonsense association with RCD vs LCA). (daher2024genotypephenotypeassociationsin pages 1-2)

3.2 Key clinical and imaging phenotypes (hallmarks)

Across cohorts and reviews, commonly reported hallmarks include: * Maculopathy (very frequent across phenotypes): maculopathy reported in 97% of the large cohort. (varela2023crb1associatedretinaldystrophies pages 9-11) * Fundus-level signs: nummular intraretinal pigmentation, white/yellow dots, telangiectasia, and preserved para-arteriolar retinal pigment epithelium (PPRPE). (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11, roshandel2021multimodalretinalimaging pages 1-2) * OCT architecture: abnormal/coarse retinal lamination and often retinal thickening (especially described in pan-retinopathy phenotypes), as well as intraretinal cysts/schisis in maculopathy variants. (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2) * Electrophysiology: some macular dystrophy patients can have normal full-field ERG but abnormal pattern ERG (PERG) P50, consistent with predominantly macular dysfunction. (varela2023crb1associatedretinaldystrophies pages 9-11)

3.3 OCTA vascular phenotype (2023)

In an OCTA observational study (genetically confirmed CRB1-retinal dystrophy, 6 patients/12 eyes), the authors conclude: “CRB1-associated retinal dystrophies are characterized by vascular alterations both in the macular and peripapillary region, as assessed by OCTA.” (rajabian2023opticalcoherencetomography pages 1-2)

3.4 Genotype–phenotype phenotypic signatures (2023–2024)

  • Null variants are significantly associated with EOSRD/LCA, and double-null genotypes were only observed in EOSRD/LCA in the large cohort. (varela2023crb1associatedretinaldystrophies pages 9-11)
  • Macular dystrophy: a recurrent in-frame deletion c.498_506del p.(Ile167_Gly169del) was found exclusively in macular dystrophy in the large cohort and appeared in all patients of a separate CRB1 macular dystrophy series discussed in the OCTA paper excerpt, consistent with a hypomorphic allele. (varela2023crb1associatedretinaldystrophies pages 9-11, rajabian2023opticalcoherencetomography pages 1-2)
  • Meta-analysis signals:
  • “Missense mutations were significantly associated with … higher risk of RCD,” whereas “homozygous nonsense mutations were associated with … high risk of LCA.” (daher2024genotypephenotypeassociationsin pages 1-2)

3.5 Quality of life

A CRB1-specific QoL longitudinal study was retrieved (Acta Ophthalmologica 2024), but the current evidence extraction did not provide interpretable results text (only metadata-level context was available). Therefore, QoL conclusions cannot be responsibly summarized from the current evidence state.

3.6 Suggested HPO terms (curation suggestions; not exhaustive)

(These are ontology mapping suggestions; they should be validated against patient-level descriptions in primary cohorts.) * Night blindness HP:0000662 * Reduced visual acuity HP:0007663 * Nystagmus HP:0000639 * Peripheral visual field loss HP:0007994 * Photoreceptor degeneration / retinal dystrophy HP:0000572 * Macular dystrophy HP:0001103 * Cystoid macular edema / macular cysts HP:0001113 * Foveal retinoschisis HP:0030507 (or related retinoschisis terms) * Hyperopia HP:0000540

4. Genetic / molecular information

4.1 Causal gene

  • CRB1 (Crumbs homolog 1). Disease in this report is driven by biallelic variants (autosomal recessive inheritance), as described across cohorts. (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2)

4.2 Variant classes and notable alleles

From the large cohort study: * Variant classifications reported: 36% pathogenic, 55% likely pathogenic, 9% VUS in the dataset’s variant interpretation. (varela2023crb1associatedretinaldystrophies pages 9-11) * A frequent allele included c.2843G>A p.(Cys948Tyr) (15 individuals; “mainly EOSRD/LCA” in the excerpt). (varela2023crb1associatedretinaldystrophies pages 9-11) * c.498_506del p.(Ile167_Gly169del) found “exclusively in MD.” (varela2023crb1associatedretinaldystrophies pages 9-11)

From the 2024 meta-analysis (439 patients): * The “commonest reported allele is p.(Cys948Tyr) (~12.48%).” (daher2024genotypephenotypeassociationsin pages 1-2) * A novel bi-allelic missense c.2936G>A; p.(Gly979Asp) was associated with rod-cone dystrophy. (daher2024genotypephenotypeassociationsin pages 1-2)

4.3 Functional consequences and modifier concepts

  • The evidence supports a loss-of-function severity gradient, with null alleles associated with more severe early-onset disease and a hypomorphic allele associated with localized maculopathy. (varela2023crb1associatedretinaldystrophies pages 9-11, rajabian2023opticalcoherencetomography pages 1-2)
  • Potential intra-genic “interaction”/modifier-like effects were suggested in the meta-analysis (e.g., variant combinations potentially modifying BCVA), but this should be treated as hypothesis-generating. (daher2024genotypephenotypeassociationsin pages 1-2)

4.4 Epigenetic information

The crumbs complex can influence epigenetic regulation in development: Owen et al. (2023) report multi-omic evidence of differential DNA methylation and transcriptional dysregulation after crumbs complex loss, with hypermethylated pathways including adhesion and signaling modules. (owen2023lossofthe pages 1-2)

5. Environmental information

No CRB1-specific environmental/lifestyle/toxic/infectious triggers were supported by the retrieved evidence. CRB1-retinopathies are primarily explained as monogenic disorders with variable expressivity. (varela2023crb1associatedretinaldystrophies pages 1-2, daher2024genotypephenotypeassociationsin pages 1-2)

6. Mechanism / pathophysiology

6.1 Cellular/anatomical locus of dysfunction

CRB1 is localized to the subapical region at/near adherens junctions of the OLM, expressed in photoreceptors and Müller glia; this is a key site where polarity/adhesion defects can disrupt retinal architecture. (stehle2024humancrb1and pages 1-2, buck2023crb1isrequired pages 1-3)

Direct abstract-supported statements: * Stehle et al. (2024): “CRB1 and CRB2 co-localize in the human retina and human iPSC-derived retinal organoids” and “our results show a stable interaction of human canonical CRB2 and CRB1 in the retina.” (stehle2024humancrb1and pages 1-2)

6.2 Crumbs polarity complex → adhesion/lamination defects → retinal dystrophy

A disease-relevant causal chain supported by experimental and patient-derived systems: 1) CRB1/Crumbs complex dysfunction (from biallelic CRB1 variants) perturbs apical–basal polarity and cell–cell adhesion at the OLM. (buck2023crb1isrequired pages 1-3, owen2023lossofthe pages 1-2) 2) This contributes to abnormal retinal lamination/coarse layering and structural disorganization, consistent with the distinctive OCT findings in human cohorts. (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2)

Owen et al. (2023) (zebrafish crb2a−/− retina + CRB1 patient-derived retinal organoids) connects crumbs loss with developmental delay and adhesion/polarity defects, and reports pathway dysregulation including Hippo and TGFβ/BMP/SMAD modules via integrated RNA-seq/methylomics. (owen2023lossofthe pages 1-2)

6.3 Endosomal trafficking and receptor recycling defects (human retinal organoids)

Buck et al. (2023) provides a mechanistic model in human iPSC retinal organoids implicating altered endosomal maturation and recycling: * They report CRB1 is required for recycling by RAB11A+ vesicles and that organoids show reduced apical CRB1 protein at the OLM alongside signatures of altered early endosomes and recycling endosomes (e.g., fewer RAB11A+ recycling endosomes, reduced VPS35/retromer component). (buck2023crb1isrequired pages 1-3, buck2023crb1isrequired pages 3-4)

This mechanistic direction aligns with the broader concept that CRB1-retinopathies are not only photoreceptor-autonomous but involve Müller glia and epithelial-like junctional organization. (buck2023crb1isrequired pages 1-3, stehle2024humancrb1and pages 13-14)

6.4 Suggested GO biological process terms (curation suggestions)

  • Establishment/maintenance of epithelial cell polarity (e.g., GO:0007163)
  • Cell–cell adhesion (e.g., GO:0098609)
  • Endosome recycling (e.g., GO:0032456)
  • Notch signaling pathway (e.g., GO:0007219)
  • Hippo signaling (pathway-mapped terms)

6.5 Suggested Cell Ontology (CL) terms

  • Müller glial cell (CL:0000688)
  • Photoreceptor cell (CL:0000210) / rod photoreceptor (CL:0000742) / cone photoreceptor (CL:0000746)

7. Anatomical structures affected

7.1 Organ/tissue/cell types

  • Primary organ: eye (retina) (varela2023crb1associatedretinaldystrophies pages 1-2)
  • Key sites/cell types: outer limiting membrane region, photoreceptors, Müller glia, and macula (maculopathy in most patients). (varela2023crb1associatedretinaldystrophies pages 9-11, stehle2024humancrb1and pages 1-2, buck2023crb1isrequired pages 1-3)

7.2 Suggested UBERON terms (curation suggestions)

  • Retina (UBERON:0000966)
  • Macula lutea (UBERON:0001880)
  • Retinal outer limiting membrane (if represented)

8. Temporal development

8.1 Onset

  • EOSRD/LCA: early childhood onset with severe impairment early in life. (varela2023crb1associatedretinaldystrophies pages 9-11)
  • RP/macular dystrophy phenotypes can present later, with variable retention of central vision depending on subtype and genotype. (varela2023crb1associatedretinaldystrophies pages 9-11, roshandel2021multimodalretinalimaging pages 1-2)

8.2 Progression / natural history (human cohort)

In the 104-patient cohort: * Severe impairment commonly occurs after age ~20 for EOSRD/LCA and after age ~40 for RP; macular dystrophy can preserve central vision into adulthood for some genotypes. (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11)

9. Inheritance and population

9.1 Inheritance

CRB1-retinopathies are predominantly autosomal recessive due to biallelic pathogenic variants. (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2)

9.2 Epidemiology (available statistics)

The retrieved evidence provides disease-contribution estimates rather than population prevalence: * CRB1 has been cited as accounting for roughly ~10% of LCA/EOSRD and up to ~6.5% of RP in the excerpted cohort synthesis. (varela2023crb1associatedretinaldystrophies pages 1-2) * In an imaging cohort paper, biallelic CRB1 mutations were summarized as accounting for ~3–9% of autosomal recessive RP and ~7–17% of LCA. (roshandel2021multimodalretinalimaging pages 1-2)

No population-level incidence/prevalence per 100,000 for CRB1-specific disease was retrievable from the current evidence set.

10. Diagnostics

10.1 Clinical testing (current practice in cohorts)

Across CRB1 cohorts and imaging studies, diagnosis and monitoring commonly involve: * Dilated fundus exam and color fundus photography (rajabian2023opticalcoherencetomography pages 1-2) * Fundus autofluorescence (FAF), including widefield FAF to visualize PPRPE and atrophy patterns (roshandel2021multimodalretinalimaging pages 1-2) * Optical coherence tomography (OCT) to assess coarse lamination, thickening, cystic/schitic change, and outer retinal atrophy (roshandel2021multimodalretinalimaging pages 1-2) * Electrophysiology (full-field ERG, pattern ERG/PERG, EOG) as indicated (rajabian2023opticalcoherencetomography pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11) * OCT angiography (OCTA) to quantify macular/peripapillary vascular alterations (rajabian2023opticalcoherencetomography pages 1-2)

10.2 Genetic testing strategy

The CRB1 imaging cohort describes confirmation by genetic testing using approaches including targeted NGS and whole-genome sequencing (in the referenced diagnostic pathways). (rajabian2023opticalcoherencetomography pages 1-2)

10.3 Differential diagnosis

Not explicitly enumerated in the extracted evidence; in practice, differential diagnosis is broad across IRDs with overlapping maculopathy/RP/LCA phenotypes.

11. Outcome / prognosis

11.1 Vision outcomes

In the large natural history cohort, visual acuity decline correlated with age and phenotype, with severe impairment tending to occur in EOSRD/LCA earlier than in RP, and macular dystrophy often preserving central vision longer. (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11)

11.2 Complications

Coats-like telangiectasia/exudative vascular changes are noted as part of the CRB1 spectrum. (varela2023crb1associatedretinaldystrophies pages 1-2, roshandel2021multimodalretinalimaging pages 1-2)

Mortality/life expectancy effects are not expected to be directly impacted by isolated retinal dystrophy and were not addressed in the extracted evidence.

12. Treatment

12.1 Standard of care / real-world implementation

The retrieved evidence emphasizes diagnosis, monitoring, and trial endpoint development rather than established CRB1-specific approved therapies.

12.2 Clinical trial endpoints and implementation-ready measures

Roshandel et al. (2021) proposes trial-suitable measures: * “Macular volume profile and microperimetry parameters may have utility as CRB1 trials end points.” (roshandel2021multimodalretinalimaging pages 1-2)

Rajabian et al. (2023) supports OCTA as an imaging biomarker domain by demonstrating quantifiable vascular alterations in CRB1 disease. (rajabian2023opticalcoherencetomography pages 1-2)

12.3 Advanced therapeutics (research and translational direction)

No CRB1-targeted interventional clinical trial records were found in the ClinicalTrials.gov interventional query used (0 records returned). (Clinical Trial Search: ffcf1a87d410)

However, multiple sources discuss a therapeutic rationale and practical constraints: * The large cohort notes therapeutic development complexity because the CRB1 coding sequence “occup[ies] nearly all the AAV packing capacity,” motivating strategies such as use of small promoters and alternative approaches (including CRB2 supplementation in animal contexts) (varela2023crb1associatedretinaldystrophies pages 13-14). * Mechanistic organoid work (Buck et al., 2023) supports CRB1 as a target by clarifying pathogenic pathways (endosomal recycling/polarity) and identifying cell types at the OLM interface. (buck2023crb1isrequired pages 1-3, buck2023crb1isrequired pages 3-4)

12.4 MAXO terms (curation suggestions)

  • Gene therapy (MAXO:0001001)
  • Genetic testing (MAXO:0000127)
  • Low vision rehabilitation (MAXO:0000486)

13. Prevention

13.1 Primary prevention

No primary prevention exists for monogenic CRB1-retinopathies.

13.2 Secondary/tertiary prevention

Secondary prevention focuses on early molecular diagnosis and monitoring to manage complications (e.g., macular cysts, exudation) and to identify potential windows for future interventional trials. (roshandel2021multimodalretinalimaging pages 1-2, varela2023crb1associatedretinaldystrophies pages 13-14)

13.3 Genetic counseling

Autosomal recessive inheritance supports counseling and cascade testing in families; detailed counseling guidance was not explicitly provided in extracted evidence.

14. Other species / natural disease

The mechanistic literature strongly leverages comparative models: * Zebrafish crb2a−/− retina used to study crumbs-complex loss impacting development and epigenetic regulation; findings were compared/validated in CRB1 patient-derived retinal organoids. (owen2023lossofthe pages 1-2) * Additional referenced systems include mouse, Drosophila, and human retina and iPSC-derived organoids, supporting evolutionary conservation of Crumbs complex function. (stehle2024humancrb1and pages 1-2, buck2023crb1isrequired pages 1-3)

No naturally occurring veterinary CRB1 disease evidence was retrievable from the current evidence state.

15. Model organisms and model systems

15.1 Human cellular models

  • Human iPSC-derived retinal organoids from CRB1 patients: show reduced apical CRB1 protein and evidence for impaired endosomal maturation/recycling (RAB11A+ recycling endosomes/retromer-related signatures). (buck2023crb1isrequired pages 1-3, buck2023crb1isrequired pages 3-4)

15.2 Animal models

  • Zebrafish crumbs-complex loss (crb2a−/−): multi-omic evidence of disrupted cell cycle progression and epigenetic transcriptional control, with pathway perturbations including Hippo and TGFβ/BMP/SMAD modules. (owen2023lossofthe pages 1-2)

Clinical trials and registries (current retrievable records)

Registry / natural history resource

  • NCT01793168 (ClinicalTrials.gov; first posted 2013; sponsor Sanford Health): Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford; Recruiting; observational registry intended “To accelerate research into rare disorders by connecting individuals…with researchers who study rare diseases.” CRB1 is listed among included conditions, and the record contains a CRB1-related registry linkage (“CRB1 Foundation / Curing Retinal Blindness Foundation Registry”). URL: https://clinicaltrials.gov/study/NCT01793168 (NCT01793168 chunk 4, NCT01793168 chunk 1)

Interventional CRB1 trials

  • No CRB1-specific interventional trials were returned by the ClinicalTrials.gov query used here. (Clinical Trial Search: ffcf1a87d410)

Recent developments (2023–2024 prioritized)

Key 2023–2024 advances supported by the retrieved evidence: 1) Largest cohort-level natural history and genotype–phenotype delineation for CRB1 disease (AJO 2023), including high maculopathy frequency and null-vs-hypomorphic genotype patterns relevant for trial readiness. (varela2023crb1associatedretinaldystrophies pages 1-2, varela2023crb1associatedretinaldystrophies pages 9-11) 2) Mechanistic clarification in human retinal organoids linking CRB1 loss to endosomal recycling defects (Stem Cell Reports 2023). (buck2023crb1isrequired pages 1-3, buck2023crb1isrequired pages 3-4) 3) Multi-omics developmental mechanism hypothesis: crumbs complex disruption associated with epigenetic dysregulation and pathway module changes (Hippo, TGFβ/BMP/SMAD) in zebrafish retina and CRB1 patient-derived organoids (J Pathol 2023). (owen2023lossofthe pages 1-2) 4) Human retina protein-complex architecture: demonstration of CRB1–CRB2 complex formation in human retina and organoids (Life Science Alliance 2024), supporting pathway-level and therapeutic design considerations. (stehle2024humancrb1and pages 1-2) 5) Genotype–phenotype meta-analysis (2024) systematically quantifying associations between variant class and phenotype, with a compiled patient count >400. (daher2024genotypephenotypeassociationsin pages 1-2)

Limitations of this report (evidence availability)

  • Standardized disease identifiers (MONDO/Orphanet/MeSH/ICD) and population prevalence/incidence were not retrievable from the available full-text set.
  • No CRB1-specific interventional trial records were found in the interventional ClinicalTrials.gov query used; only a broad registry record including CRB1 could be extracted.
  • Quality-of-life and detailed management/supportive care recommendations could not be summarized from the extracted evidence fragments.

Embedded summary table

The following table compacts the key disease entities, phenotypes, imaging hallmarks, and genotype–phenotype signals supported by the extracted evidence.

Disease entity Inheritance Hallmark clinical/imaging features Key genotype-phenotype associations / variants Key quantitative stats
EOSRD / LCA8 Autosomal recessive; biallelic CRB1 variants Very early-onset severe retinal dystrophy; low vision in first 2 decades; maculopathy common; abnormally laminated/coarsely laminated and often thickened retina on OCT; macular thinning reported in EOSRD/LCA cohorts; nummular pigment, white/yellow dots, telangiectasia may be present; high hyperopia common; severe visual impairment often develops after age 20 Strong association with null / loss-of-function alleles; double-null genotypes reported only in EOSRD/LCA; p.(Cys948Tyr) common and mainly seen in EOSRD/LCA; homozygous nonsense variants linked to higher LCA risk; loss-of-function alleles additively increase LCA risk, with nonsense > indels In a 104-patient cohort, EOSRD/LCA represented 52%; in an 11-proband eoRD series, 81.8% presented as LCA; in a 439-patient meta-analysis, CRB1 missense/nonsense patterns significantly stratified RCD vs LCA risk; CRB1 contributes ~10% of LCA/EOSRD overall and ~7–17% of LCA cases in cited summaries
RP12 / CRB1-associated retinitis pigmentosa Autosomal recessive; biallelic CRB1 variants Progressive rod-cone or generalized retinal dysfunction; severe visual impairment often after age 40; preserved para-arteriolar RPE (PPRPE), nummular intraretinal pigmentation, coarse retinal lamination and retinal thickening on OCT; perifoveal thickening; Coats-like / exudative telangiectatic changes may occur; OCTA shows reduced deep capillary plexus and choriocapillaris vessel density with broader macular/peripapillary vascular alterations Missense variants associated with absence of macular pigments, pale optic disc, peripheral pigmentation, and higher rod-cone dystrophy risk; p.(Cys948Tyr) is a frequent allele across CRB1 disease; some RP/MD phenotypes retain preserved foveal architecture and central function; AFSM described in compound heterozygotes c.[2843G>A];[498_506del] In the 104-patient cohort, RP represented 25%; CRB1 accounts for up to ~6.5% of RP overall and ~3–9% of autosomal recessive RP in cited summaries; in one imaging cohort, symptom onset averaged 9 years and mean baseline age was 35 years
Macular dystrophy / CRB1 maculopathy Autosomal recessive; biallelic CRB1 variants Macula-centered disease with relatively preserved central vision into adulthood in some patients; early intraretinal cysts / schitic or cystoid maculopathy may evolve to bull’s-eye or outer retinal atrophy; abnormal PERG may occur despite normal full-field ERG; preserved foveal architecture can be seen; peripheral changes may be absent or limited In-frame c.498_506del p.(Ile167_Gly169del) found exclusively in MD in one large cohort and in all 7 patients of a macular dystrophy series, consistent with a hypomorphic/milder localized maculopathy allele; null alleles can occur in MD but often with milder / hypomorphic variants; homozygous c.2506C>A p.(Pro836Thr) linked to mild, stable MD with elevated IOP/CME in later evidence summaries In the 104-patient cohort, MD represented 23%; 7/7 patients in one macular dystrophy series carried p.(Ile167_Gly169del); median age at presentation in that series was 21 years with modest VA impairment; seven patients in the large cohort had preserved foveal architecture with good central vision
Cone-rod / rod-cone dystrophy Autosomal recessive; biallelic CRB1 variants Generalized cone and rod dysfunction or rod-cone pattern on electrophysiology; reduced central vision; may overlap clinically with RP or early-onset disease; coin-like yellow-white retinal spots and para-arteriolar RPE retention reported in eoRD cohorts Novel bi-allelic missense c.2936G>A p.(Gly979Asp) associated with rod-cone dystrophy; missense variants overall were associated with higher rod-cone dystrophy risk than nonsense variants Cone-rod dystrophy is less common than EOSRD/LCA, RP, and MD in the cited cohorts; among 20 patients tested for contrast sensitivity, 3 had CORD; in the 439-patient meta-analysis, missense variants were significantly enriched in RCD-associated phenotypes
Foveal retinoschisis / schitic-cystoid maculopathy / AFSM Autosomal recessive; biallelic CRB1 variants Foveal retinoschisis or cystic/schitic macular changes on OCT; can be early-onset and may later resolve leaving macular atrophy; asymptomatic fenestrated slit maculopathy (AFSM) may show localized outer retinal disruption and parafoveal cone loss despite normal acuity, fundus appearance, and foveal sensitivity Maculopathy including schitic/cystoid change has been associated with CRB1; AFSM reported in siblings with compound heterozygous c.[2843G>A];[498_506del]; c.498_506del is repeatedly linked to mild macular-centered phenotypes AFSM was reported in 2 siblings within a 12-patient imaging cohort; in that cohort, preserved central retinal function by microperimetry was documented in 6 patients, and the perifoveal-to-foveal retinal volume ratio was greater than controls in 89% (8/9) of RP/MD patients

Table: This table compacts the main disease entities grouped under CRB1 retinal dystrophies, highlighting inheritance, hallmark phenotypes, genotype-phenotype signals, and quantitative findings useful for clinical characterization and knowledge-base curation.

References

  1. (varela2023crb1associatedretinaldystrophies pages 1-2): Malena Daich Varela, Michalis Georgiou, Yahya Alswaiti, Jamil Kabbani, Kaoru Fujinami, Yu Fujinami-Yokokawa, Shaheeni Khoda, Omar A. Mahroo, Anthony G. Robson, Andrew R. Webster, Alaa AlTalbishi, and Michel Michaelides. Crb1-associated retinal dystrophies: genetics, clinical characteristics, and natural history. American Journal of Ophthalmology, 246:107-121, Feb 2023. URL: https://doi.org/10.1016/j.ajo.2022.09.002, doi:10.1016/j.ajo.2022.09.002. This article has 50 citations and is from a domain leading peer-reviewed journal.

  2. (varela2023crb1associatedretinaldystrophies pages 9-11): Malena Daich Varela, Michalis Georgiou, Yahya Alswaiti, Jamil Kabbani, Kaoru Fujinami, Yu Fujinami-Yokokawa, Shaheeni Khoda, Omar A. Mahroo, Anthony G. Robson, Andrew R. Webster, Alaa AlTalbishi, and Michel Michaelides. Crb1-associated retinal dystrophies: genetics, clinical characteristics, and natural history. American Journal of Ophthalmology, 246:107-121, Feb 2023. URL: https://doi.org/10.1016/j.ajo.2022.09.002, doi:10.1016/j.ajo.2022.09.002. This article has 50 citations and is from a domain leading peer-reviewed journal.

  3. (roshandel2021multimodalretinalimaging pages 1-2): Danial Roshandel, Jennifer A. Thompson, Rachael C. Heath Jeffery, Danuta M. Sampson, Enid Chelva, Terri L. McLaren, Tina M. Lamey, John N. De Roach, Shane R. Durkin, and Fred K. Chen. Multimodal retinal imaging and microperimetry reveal a novel phenotype and potential trial end points in crb1-associated retinopathies. Translational Vision Science & Technology, 10:38, Feb 2021. URL: https://doi.org/10.1167/tvst.10.2.38, doi:10.1167/tvst.10.2.38. This article has 26 citations and is from a peer-reviewed journal.

  4. (daher2024genotypephenotypeassociationsin pages 1-2): Ahmad Daher, Malak Banjak, Jinane Noureldine, Joseph Nehme, and Said El Shamieh. Genotype-phenotype associations in crb1 bi-allelic patients: a novel mutation, a systematic review and meta-analysis. BMC Ophthalmology, Apr 2024. URL: https://doi.org/10.1186/s12886-024-03419-4, doi:10.1186/s12886-024-03419-4. This article has 7 citations and is from a peer-reviewed journal.

  5. (rodriguezmartinez2025expandingtheclinical pages 1-2): Ana Catalina Rodriguez-Martinez, Oliver R. Marmoy, Katrina L. Prise, Robert H. Henderson, Dorothy A. Thompson, and Mariya Moosajee. Expanding the clinical spectrum of crb1-retinopathies: a novel genotype–phenotype correlation with macular dystrophy and elevated intraocular pressure. International Journal of Molecular Sciences, 26:2836, Mar 2025. URL: https://doi.org/10.3390/ijms26072836, doi:10.3390/ijms26072836. This article has 3 citations.

  6. (stehle2024humancrb1and pages 1-2): Isabel F Stehle, Joel A Imventarza, Franziska Woerz, Felix Hoffmann, Karsten Boldt, Tina Beyer, Peter MJ Quinn, and Marius Ueffing. Human crb1 and crb2 form homo- and heteromeric protein complexes in the retina. Life Science Alliance, 7:e202302440, Apr 2024. URL: https://doi.org/10.26508/lsa.202302440, doi:10.26508/lsa.202302440. This article has 6 citations and is from a peer-reviewed journal.

  7. (buck2023crb1isrequired pages 1-3): Thilo M. Buck, Peter M.J. Quinn, Lucie P. Pellissier, Aat A. Mulder, Aldo Jongejan, Xuefei Lu, Nanda Boon, Daniëlle Koot, Hind Almushattat, Christiaan H. Arendzen, Rogier M. Vos, Edward J. Bradley, Christian Freund, Harald M.M. Mikkers, Camiel J.F. Boon, Perry D. Moerland, Frank Baas, Abraham J. Koster, Jacques Neefjes, Ilana Berlin, Carolina R. Jost, and Jan Wijnholds. Crb1 is required for recycling by rab11a+ vesicles in human retinal organoids. Stem Cell Reports, 18:1793-1810, Sep 2023. URL: https://doi.org/10.1016/j.stemcr.2023.07.001, doi:10.1016/j.stemcr.2023.07.001. This article has 14 citations and is from a domain leading peer-reviewed journal.

  8. (owen2023lossofthe pages 1-2): Nicholas Owen, Maria Toms, Yuan Tian, Lyes Toualbi, Rose Richardson, Rodrigo Young, Dhani Tracey‐White, Pawan Dhami, Stephan Beck, and Mariya Moosajee. Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle progression in the developing retina. The Journal of Pathology, 259:441-454, Feb 2023. URL: https://doi.org/10.1002/path.6056, doi:10.1002/path.6056. This article has 11 citations.

  9. (rajabian2023opticalcoherencetomography pages 1-2): Firuzeh Rajabian, Alessandro Arrigo, Lorenzo Bianco, Alessio Antropoli, Maria Pia Manitto, Elisabetta Martina, Francesco Bandello, Jay Chhablani, and Maurizio Battaglia Parodi. Optical coherence tomography angiography in crb1-associated retinal dystrophies. Journal of Clinical Medicine, 12:1095, Jan 2023. URL: https://doi.org/10.3390/jcm12031095, doi:10.3390/jcm12031095. This article has 4 citations.

  10. (buck2023crb1isrequired pages 3-4): Thilo M. Buck, Peter M.J. Quinn, Lucie P. Pellissier, Aat A. Mulder, Aldo Jongejan, Xuefei Lu, Nanda Boon, Daniëlle Koot, Hind Almushattat, Christiaan H. Arendzen, Rogier M. Vos, Edward J. Bradley, Christian Freund, Harald M.M. Mikkers, Camiel J.F. Boon, Perry D. Moerland, Frank Baas, Abraham J. Koster, Jacques Neefjes, Ilana Berlin, Carolina R. Jost, and Jan Wijnholds. Crb1 is required for recycling by rab11a+ vesicles in human retinal organoids. Stem Cell Reports, 18:1793-1810, Sep 2023. URL: https://doi.org/10.1016/j.stemcr.2023.07.001, doi:10.1016/j.stemcr.2023.07.001. This article has 14 citations and is from a domain leading peer-reviewed journal.

  11. (stehle2024humancrb1and pages 13-14): Isabel F Stehle, Joel A Imventarza, Franziska Woerz, Felix Hoffmann, Karsten Boldt, Tina Beyer, Peter MJ Quinn, and Marius Ueffing. Human crb1 and crb2 form homo- and heteromeric protein complexes in the retina. Life Science Alliance, 7:e202302440, Apr 2024. URL: https://doi.org/10.26508/lsa.202302440, doi:10.26508/lsa.202302440. This article has 6 citations and is from a peer-reviewed journal.

  12. (Clinical Trial Search: ffcf1a87d410): Clinical Trials Search via ClinicalTrials.gov: CRB1 AND (retinal dystrophy OR Leber congenital amaurosis OR retinitis pigmentosa) AREA[StudyType]INTERVENTIONAL

  13. (varela2023crb1associatedretinaldystrophies pages 13-14): Malena Daich Varela, Michalis Georgiou, Yahya Alswaiti, Jamil Kabbani, Kaoru Fujinami, Yu Fujinami-Yokokawa, Shaheeni Khoda, Omar A. Mahroo, Anthony G. Robson, Andrew R. Webster, Alaa AlTalbishi, and Michel Michaelides. Crb1-associated retinal dystrophies: genetics, clinical characteristics, and natural history. American Journal of Ophthalmology, 246:107-121, Feb 2023. URL: https://doi.org/10.1016/j.ajo.2022.09.002, doi:10.1016/j.ajo.2022.09.002. This article has 50 citations and is from a domain leading peer-reviewed journal.

  14. (NCT01793168 chunk 4): Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford. Sanford Health. 2010. ClinicalTrials.gov Identifier: NCT01793168

  15. (NCT01793168 chunk 1): Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford. Sanford Health. 2010. ClinicalTrials.gov Identifier: NCT01793168